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I. INTRODUCTION 
1. Orphan G-protein coupled receptors (oGPCR) and the reverse pharmacology 
approach 
Nociceptin/orphanin FQ (N/OFQ) and its receptor (NOP) constitute a novel peptide-receptor 
system, widely expressed centrally and in the periphery. N/OFQ is involved in pain 
transmission, anxiety and response to stress, learning and memory, food intake and locomotor 
activity. Additionally, N/OFQ controls some functions of the renal, cardiovascular, respiratory 
and gastrointestinal systems. Therefore, it is an emerging molecular target for the development 
of novel therapeutics for several disease states. 
G-protein coupled receptors (GPCR) are one of the largest family of proteins that are the 
main modulators of intercellular interactions and regulate activities in the human body and 
particularly in the central nervous system (CNS). They are targets of most of the primary 
messengers including the neurotransmitters, all the neuropeptides, the glycoprotein hormones, 
lipid mediators and other small molecules; thus have considerable pharmaceutical interest. 
Drugs that are acting on GPCRs are used to treat numerous disorders. More than 30 % of the 
approximately 500 clinically used drugs, are modulators of GPCR function, representing around 
9 % of the global pharmaceutical sales, making GPCRs the most successful of any target class in 
terms of drug discovery [1 ]. 
After the completion of the Human Genome Sequencing Project, many genes 
(approximately 720) that belong to the GPCR superfamily have been identified. Half of these 
encode chemosensory receptors (e.g., olfactory, gustatory, chemokine and chemoattractant), 
while the remaining half regulate responses involving endogenous transmitters. From the latter, 
for approximately 210 receptors had the individual natural ligands been identified, and the 
remaining (150) receptors are called orphan GPCRs (oGPCRs) with unidentified endogenous 
ligand or unknown function. Identification of a novel transmitter that naturally activates an 
oGPCR provides more information about the function of that receptor. There are several 
experimental approaches to identify a transmitter: screening of putative small molecule and 
peptide ligands, reverse pharmacology, and the use of bioinformatics to predict candidate 
ligands. The first deorphanization activities began in the mid 80s by testing the potential 
transmitters, and the method was named the reverse pharmacology approach. A variation of the 
reverse pharmacology approach was developed in 1995: instead of screening potential 
transmitters, extracts of tissues were used as sources of new transmitters. The orphan receptor 
strategy was proven to be successful with the discovery of a new neuropeptide, 
nociceptin/orphanin FQ (N/OFQ) as the transmitter of the oGPCR ORL-1 [2, 3], In this strategy, 
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by the help of functional genomics, oGPCRs are expressed in a recombinant expression system, 
such as mammalian cells, yeast, or Xenopus melanophores. Following expression, candidate 
ligands (including small molecules, peptides, proteins, lipids, or tissue extracts) are screened 
against the receptor to identify molecules capable of interacting specifically with that receptor. 
The identification of a candidate ligand is detected according to the activation of an intracellular 
signalling cascade. An activating ligand (or a hit molecule) will be identified by its ability to 
cause a concentration-dependent increase in the activity of a signalling cascade. Once identified, 
the ligand may be further tested against other GPCRs to determine its activity and selectivity 
profile prior to being used in a cell-based, tissue and in some cases whole-animal experiments, 
in order to study the physiological role of the receptor. 
The first successful example of the novel approach (the discovery of N/OFQ) was followed 
by the identification of other novel bioactive peptides such as: hypocretins and orexins 
(Hcrts/Oxs), prolactin-releasing peptide (PrRP), apelin, ghrelin, melanin-concentrating hormone 
(MCH), urotensin 11 (UII), neuromedin U (NMU), metastin, neuropeptide B (NPB), 
neuropeptide W (NPW) and neuropeptide S (NPS). Each of these discoveries was a landmark in 
its field [4], 
2. NOP receptor 
2.1. Molecular cloning of NOP receptor 
Molecular cloning of the 6-opioid peptide receptor [5, 6] was soon followed by the cloning 
of the p- [7] and the K-opioid peptide (MOP and KOP) receptors [8], Further attempts to clone 
additional opioid receptor types and/or subtypes, by hybridization screening at low stringency 
with opioid receptor cDNA probes, or using probes generated by selective amplification of 
genomic DNA with degenerative primers led several research groups to isolate a cDNA 
encoding a homologous protein with a high degree of sequence similarity to the opioid receptors 
[9], The novel clones displayed approximately 50 % identity with the traditional opioid 
receptors overall, with the transmembrane regions showing even higher homologies of up to 
80 %. Despite their close homology to the other opioid receptors, opioids displayed very low 
affinities towards the ORL-1 (Opioid Receptor Like-1) receptor, thus it was considered an 
orphan receptor until the discovery of the endogenous ligand. ORL-1 was subsequently named 
NOP (Nociceptin/Orphanin FQ peptide) receptor according to the IUPHAR nomenclature [10], 
NOP receptor was cloned from several species like human: ORL1 [11]; mouse: KOR-3 ref. [12, 
13], MOR-C [14]; rat: LC132 ref. [15], XOR1 ref. [16, 17], Ratxorl ref. [18], C3 ref. [19], 
ROR-C [20, 21]; pig: NOP receptor [22], 
The human NOP receptor protein consists of 370 amino acids [11] and contains seven trans-
membrane (TM) domains (Fig. 1). Like most GPCRs, human NOP receptor displays many 
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putative consensus sites for post-translational modifications like i) three asparagine residues 
within Asn-Xxx-Ser/Thr motifs for N-linked glycosylation, ii) a pair of conserved cysteine 
residues which may form a disulphide bridge between extracellular loops (EL) 1 and 2 and iii) 
putative palmitoylation sites downstream of TM segments. Also all cytoplasmic domains 
contain a number of Ser/Thr residues representing potential sites for phosphorylation, a process 
known to be involved in desensitization [11], 
2.2. The NOP receptor gene 
The NOP receptor gene, Oprll, is located at the 
q 13.2-13.3 region of the human chromosome 20 ref. 
[23], In terms of intron-exon organization, the NOP 
receptor gene is nearly identical to that of the 5-, p-, 
and K-opioid receptors, suggesting that the four genes 
have evolved from a common ancestor and hence 
belong to the same family [24], Indeed, the NOP 
receptor appears to be evolutionary as old as the opioid 
receptors, since NOP receptor-like genomic sequences 
have been reported in teleost [25], in cartilaginous fish 
[26], in sturgeon [27] and in zebra fish [28], 
mi ;«»< Y ».„JWLOJ'2 
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Fig. 1: The NOP receptor model from Topham et al 1998 [29], 
2.3. NOP receptor heterogeneity 
There are some indications for the existance of multiple NOP receptors, which originates 
from the pharmacological (the biphasic effects of the N/OFQ peptide/NOP receptor system on 
pain and locomotion) and receptor binding studies (presence of high and low affinity states of 
the NOP receptor in mouse brain homogenates [30, 31]). Although the pharmacological studies 
have not firmly established the existence of NOP receptor subtypes [32], the NOP receptor 
heterogeneity is still an open question. The receptor subtypes may arise from splice variants 
([16, 33, 34]) of the NOP receptor cDNA [9], It has been investigated that the Oprll gene 
transcript undergoes alternative splicing. So far, five splice variants of NOP receptor mRNA 
have been isolated. Except one splice variant that encodes a functional receptor which has been 
isolated from human tissue [23], none of the other variants encode a full-length receptor [35], 
but rather non-functional truncated receptors. 
Alternatively, apparent NOP receptor heterogeneity may arise from posttranslational 
modifications, expression of an yet unknown receptor gene or functional interaction of the NOP 
3 
receptor with other receptors or proteins [36], The use of NOP receptor deficient (knockout) 
mice devoid of any N/OFQ binding [37] revealed the extinction of a separate NOP receptor 
encoded by an independent gene. Thus, the functional modification of the NOP receptor has to 
be elucidated at the protein level. Receptor oligomerization (formation of homo and hetero 
oligomers) in particular, heterodimerization of distinct but structurally related GPCRs occurs in 
plasma membrane and generates pharmacological and signalling properties that are different 
than those of individual receptors [38, 39], The synergic or antagonistic interactions between 
different GPCRs that are co expressed in the same cell may be due to dimerization. 
Heterodimerization of the NOP receptor with opioid receptors has been investigated and so far 
just the formation of NOP-MOP receptor heterodimers were reported within the studies in cell 
lines co-transfected with NOP and MOP receptors. It can be postulated that NOP-MOP receptor 
heterodimerization and the resulting impairment of the MOP receptor activated signalling 
pathways contributes to the NOP receptor mediated antiopioid effects in the brain [40, 41]. 
Further studies are necessary in particular to investigate the possible oligomerization with 
x-opioid (KOP) receptors. Due to the structural homologies of the endogenous ligands and the 
reasonable affinity of dynorphin derivatives (Dyn R8) for inhibition of forskolin-stimulated 
cAMP accumulation at the NOP receptor [42] and at the [125I](Tyr,0)N/OFQ(l-l 1) binding site 
in mouse brain [43], heterodimer formation with KOP receptor can be expected. 
3. The Endogenous Ligand Nociceptin/Orphanin FQ 
3.1. Isolation 
Soon after the cloning of the orphan opioid receptor-like 1 ('NOP' according to the current 
IUPHAR nomenclature) receptor, Chinese Hamster Ovary (CHO) cells transfected with the 
orphan receptor were used to fish the endogenous ligand. Because the ORL1 transcripts were 
particularly abundant in the hypothalamus, two independent research groups used crude extracts 
from rat brain [3] and porcine hypothalamus [2] to screen the crude tissue fractions for the 
adenylyl cyclase inhibitory activity as a functional assay in the cell lines stably transfected with 
ORL1. The fractions that were able to inhibit the adenylyl cyclase activity, were further 
fractionated through reverse-phase high-performance liquid chromatography (rpHPLC). The 
purification and mass spectrometry analyses yielded to identify a heptadecapeptide (Fig.2), the 
sequence of the peptide was determined and synthesized. The synthetic peptide was shown to 
inhibit the forskolin-stimulated accumulation of cAMP in the CHO cells transfected with the 
'orphan' receptor, while showing no activity in non-transfected control cells. In vivo studies 
revealed that this peptide following intracerebroventricular (i.e.v.) administration in mice 
produced hyperalgesia in the hot plate [3] and tail flick [2] tests. Decrease in the locomotor 
activity but no analgesia was also observed in the hot plate test [2]. The french group named this 
4 
peptide 'nociceptin' to denote its pronociceptive activity, while the swiss authors called it 
'orphanin FQ' due to its high affinity to the orphan receptor with the indications of the peptide's 
first and last amino acids phenylalanine (Phe, F) and glutamine (Gin, Q), respectively. The latest 
terminology of this peptide given by IUPHAR is nociceptin/orphanin FQ (N/OFQ) [10]. Both 
N/OFQ and the NOP receptor share sequence homologies with the opioid peptide ligand 
Dynorphin A and the K- opioid receptor, respectively. In Fig. 2, the structural similarities of the 
peptides are shown Despite the similarities, these peptides are functionally quite distinct. 
N/OFQ has no significant affinity for any of the opioid receptors [42], 
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Fig. 2: Structural similarities between dynorphin A and N/OFQ amino acid sequences. 
3.2. Precursor Protein 
Like all neuropeptides, N/OFQ is also derived from a larger polypeptide precursor (the 
length is 176 amino acids in human) prepronociceptin (ppN/OFQ) [44, 45], The ppN/OFQ 
genes were shown to be highly conserved in three species from which they had been isolated. 
The ppN/OFQ gene is located in the human chromosome 8 (8p21) ref [44], Moreover the 
organizational features that are strikingly similar in the precursors of endogenous opioid 
peptides, suggests that the four genes belong to the same family hence they have a common 
evolutionary origin [44, 45], 
Signal peptide 
WLCDUILSLFSSVFSSCQRDCLTCQEKLHPALDSFDLEVCILECEEKVFPSPLWTPCTKVMARS 
bPNP-2 bPNP-3 (NOCiSTATIN) 
SWQLSPAAPEHVAAALYQPRASEMQHLR-'MPRVRSLFCEClE^ PEPGMEEAGEMEQKQLO fFGGF 
NOCICEPTIN/ORPHANIN FQ bPNP-4 (ORPHANIN FQ2) bPNP-5 
TGARKSARKLANQKR'FSEFMRQYLVLSMQSSQRRRTLHQNGNV 
Fig. 3: The amino acid sequence of the human precursor protein of N/OFQ (ppN/OFQ). The 
signal peptide and putative peptides derive from the same precursor (eg. N/OFQ, N/OFQ II and 
nocistatin) are indicated by upper lines. The conserved amino acids are shown as bold and the 
putative proteolytic cleavage motifs are shown in blue. 
The primary structure of the precursor protein contains the typical structural elements of a 
neuropeptide precursor: an amino terminus signal peptide necessary for its secretion, several 
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pairs of basic amino acids that represent possible sites of cleavage for precursor maturation or 
for transcriptional regulation [46], Several biologically relevant peptides may derive from the 
N/OFQ precursor (Fig. 3). Apparently two additional peptides are excised from the same 
precursor: orphanin FQ2 or N/OFQ II and nocistatin [47], None of them bind to NOP receptor 
[44, 45], and until now specific receptors for them have not been identified, although an 
unidentified receptor was proposed for N/OFQ II [48], Orphanin FQ2 is a heptadecapeptide 
terminating with a FQ couple similar to N/OFQ. It has been found to be biologically active, 
stimulating locomotor activity in mice [49], inducing antinociception both supraspinally and 
spinally [50] and inhibiting gastrointestinal transit [50], Nocistatin which antagonizes several 
functions of N/OFQ, is the other peptide derived from the same precursor [47], It has been 
found in many studies to be inactive per se but was able to reverse several effects of N/OFQ 
such as induction of allodynia after spinal administration in mice [47, 51], inhibition of 
glutamate release from rat brain slices [52], impairment of learning and memory in mice [53], 
However it has been reported that nocistatin applied to rats i.e. v. or i t. can cause antinociception 
in the carrageenan test [54] or in the formalin test [55], Interestingly nocistatin or its C-terminal 
hexapeptide exerts anxiogenic-like effect in mice [56]. 
3.3. Metabolism of N/OFQ 
Once N/OFQ is released from the neurons, it is metabolised to inactive fragments by 
different types of proteolytic enzymes such as aminopeptidase N (APN) generating N/OFQ 
(2-17) that does not bind to NOP receptor. Endopeptidase 24.15 (EP 24.15) [57] acts on the 
peptide bonds Ala7-Arg8, Alan-Arg12, Argl2-Lys° and releases inactive compounds, 
Endopeptidase 24.11 (EP 24.11) acts on the cleavage site (Lysl3-Leu14 bond) and plays a major 
role in the initial stage of N/OFQ metabolism in mouse spinal cord [58], N/OFQ(l-13) is the 
active metabolite that has less affinity than N/OFQ to the NOP receptor [59], Also the 
carboxypeptidase B acting on the arginine, lysine and ornithine residues in the C-terminal may 
play a minor role in the degredation of N/OFQ [57, 58], The schematic illustration of the 
degredation of N/OFQ can be seen in Fig. 4. 
FGGFTGARK * SARK 
EP 24.11 
FGGFTGARKSARK * LANQ 
I KP 24.11 Fig. 4: N/OFQ metabolism and the 
F G G F T G A R K S A R K L A N Q metabolites. APN, aminopeptidase 
APN 
N; EP, endopeptidase. 
F + GGFTGARKSARKLANO \ \ FGGFTGARKSAR • KLANQ 
FGGFTGARKSA < RKLANQ 
4 FGGFIGA + RKSARKLANQ 
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3.4. Transgenic Mice 
As an alternative to the pharmacological tools such as stable NOP receptor antagonists, the 
developments in molecular biology provided the molecular tools for specific gene deleting Up 
to date transgenic 'knockout' mice devoid of N/OFQ precursor [60, 61] as well as mice lacking 
the NOP receptor [37, 62] have been generated and studied. NOP receptor knockout (NOP "') 
mice do not display differences in nociceptive threshold or anxiety-related behaviours when 
compared with wild-type animals [62, 63], however NOP knockout mice display an 
antidepressant-like phenotype [64], While the knockout mice for the ppN/OFQ gene 
(ppN/OFQ-' ) presents an elevated basal nociceptive threshold and an anxiogenic-like phenotype 
[60], This discrepancy between phenotypes could possibly arise from the existence of NOP 
receptor subtypes, or the different genetic backgrounds of mice. However it should not be 
underestimated that, the biological activities of nocistatin or orphanin FQ2 that are mediated by 
a receptor other than NOP receptor, could contribute to the phenotype differences [65], 
4. Tissue distribution of NOP receptor and N/OFQ 
Before identification of the endogenous ligand, the distribution of the NOP receptor 
transcripts in murine tissues was investigated by in situ hybridization [11, 15, 17, 19, 20], 
Northern blot [18] and RT-PCR [16] analyses. Immunolocalization of the receptor protein, using 
specific antibodies provided a detailed mapping of the rat brain [66] and spinal cord [67], 
Following the identification of N/OFQ, the distribution of the NOP receptor was confirmed with 
autoradiographic studies based on agonist stimulated [35S]GTPYS binding [68] and binding with 
labelled N/OFQ analogs [69, 70], Additionally, NOP receptor binding is compared and shown to 
be in good correlation with mRNA hybridization. Regions with NOP receptor binding typically 
express NOP mRNA as well, although the levels of mRNA and NOP binding do not always 
match very closely. [71] 
The NOP receptor is widely expressed in the CNS, in particular in the forebrain (cortical 
areas, olfactory regions, limbic structures: hippocampus and amygdala, thalamus), throughout 
the brainstem (central periaqueductal gray, substantia nigra, several sensory and motor nuclei), 
and in both dorsal and ventral horns of the spinal cord [71, 72]. Regions only light 
immunohistochemical labelling for NOP receptors are observed in the caudate-putamen and the 
cerebellum [66] (in contrast to rodents, in humans a considerable amount of NOP receptors have 
been found in the cerebellum [36]). The NOP receptor has also been identified in the peripheral 
nervous system and several other organs. Thus, the NOP receptor is expressed in smooth 
muscles, in peripheral ganglia and in the immune system. It has been detected in rat intestine 
and vas deferens, porcine gastrointestinal tract and kidney, also in rat retina and heart [72], 
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It is worth to mention that NOP receptors co-express with MOP receptors in the dorsal horn 
of the spinal cord, the hippocampal formation and the caudate putamen [66, 73] in the midbrain 
periaqueductal gray (PAG) and the nucleus raphe magnus (NRM) [74] 
The localization of N/OFQ-immunoreactive fibers and terminals and/or the localization of the 
N/OFQ peptide precursor mRNA is more limited, compared with that of the NOP receptor. 
Limbic areas, however, highly express N/OFQ, in particular the bed nucleus of the stria 
terminals, and the amygdala nuclei [75, 76], A matching pattern of N/OFQ and NOP receptor 
expression in the human and rodent central nervous system has been observed [23, 36, 77], In 
the periphery mRNA of N/OFQ was detected in rat ovary, human spleen, lymphocytes, and 
fetal, but not adult kidney [44, 45], Moreover, under physiological conditions N/OFQ is present 
in the plasma of humans (~ 10 pg/ml) [78], in several pathological conditions such as female 
fibromyalgia syndrome [79], postpartum depression [80], Wilson's disease [81], hepatocellular 
carcinoma [82], pain and chronic pain [83], cluster headache [84], migraine without aura [85] 
N/OFQ levels were detected to be either increased or decreased (in the case of the latter two) in 
the plasma. 
Analysis of N/OFQ and opioid stimulated [35S]GTPyS binding autoradiography in guinea 
pig brain showed a unique distribution of the NOP receptor which might explain the different, or 
sometimes opposite pharmacological effects of N/OFQ and opioids [68], Due to the widespread 
distribution of N/OFQ peptide and NOP receptor, this novel system is associated with a large 
number of physiological responses and probably contributes to the homeostasis by modulating 
neuronal circuitry [72], This might explain why the NOP receptor knockout mice has not an 
obvious impact (else than the unrestrained nociceptive response and disregulation of hearing 
ability) [62] and also why pharmacological effects of N/OFQ are sometimes contradictory 
(e.g. in pain and locomotor tests) depending on the locus of injection and dose [72], 
5. Cellular Actions of N/OFQ 
Since N/OFQ and opioid receptors are members of GPCR superfamily, they are capable of 
interacting with specific GTP binding proteins (i.e., G-proteins). G-proteins are membrane 
bound/associated heterotrimeric proteins composed of a, p, y subunits. Because of the high 
sequence homology in the putative intracellular loops (IL) of NOP and opioid receptors, it was 
anticipated that the NOP receptor couples to the same G-protein regulated cellular effectors as 
do the opioid receptors. Early postreceptor events induced by N/OFQ are: 
i) inhibition of forskolin-stimulated cellular cAMP accumulation. Forskolin is used to directly 
activate adenylyl cyclase and consequently increase cAMP production. 
ii) inhibition of voltage-gated N-type calcium channels 
iii) activation of inwardly-rectifying potassium conductance 
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There is evidence for N/OFQ mediated activation of additional signalling pathways It has 
been shown that NOP receptor activation stimulates phospholipase C via a pertussis toxin 
(PTX)-sensitive G-protein (Gi/0 family), to increase intracellular Ca2 concentration which then 
activates phosholipase C [86], Both NOP and MOP receptors were reported to mediate PTX-
sensitive mitogen-activated protein (MAP) kinase activation via signaling pathway using the 
Gipy [87], However, these effects were observed only in recombinant cells, thus, further studies 
are required especially in non-recombinant (i.e., native cellular) systems. 
6. N/OFQ and neurotransmitter release 
N/OFQ-NOP receptor system has an important role in neurotransmitter release. N/OFQ 
reduces neuronal excitability and presynaptic transmitter secretion primarily by acting on ion 
conductances [24]. In the central nervous system: studies using synaptosomes and brain slices 
revealed that N/OFQ inhibits the release of noradrenaline (NA), serotonine (5-HT), dopamine 
(DA), acetylcholine (AcH), y-aminobutyric acid (GABA), and glutamate (nicely reviewed [88]). 
In the peripheral nervous system: studies showed the general modulatory effects (mostly 
inhibitory) of N/OFQ on neurotransmitter release from sympathetic, parasympathetic, 
nonadrenergic-noncholinergic (NANC) and sensory nerve endings (presynaptical inhibitory 
function). On the respiratory, cardiovascular, genitourinary and gastrointestinal systems N/OFQ 
exerts inhibitory effects [89], 
7. Other Biological Actions of N/OFQ 
Due to the widespread distribution of N/OFQ and NOP receptor, this peptidergic system is 
involved in a broad spectrum of biological actions. The role of this peptidergic system has been 
explored intensely with the pharmacological and biological tools available, such as i) antisense 
oligonucleotides targeting NOP receptor or ppN/OFQ gene, ii) antibodies directed against 
N/OFQ, iii) transgenic mice in which the receptor or the peptide precursor genes have been 
genetically eliminated, iv) available stable and highly potent antagonists (preferably non-
peptide) [32], Some of the central effects of N/OFQ can be seen in Table 1. 
On the central level N/OFQ modulates: nociception [2, 3, 90], spontaneous locomotor 
activity [2], responses to stress and anxiety [91], food intake [92], rewarding actions of opioids 
[93] and ethanol [94], addiction [95, 96], learning and memory processes [97], On the peripheral 
level N/OFQ has effects like: inhibition of gastrointestinal motility [98], inhibition of 
contractions of bronchus and trachea in the airway [99, 100, 101], broncho constriction induced 
by capsaicin [102], inhibition of coughing reflex [103], bradycardia and hypotension [104, 105], 
increase blood pressure and heart rate [106] in the cardiovascular system, diuretic and 
antinatriuretic responses on the renal function [107, 108], suppression of micturition reflex 
[109]. 
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Table 1: Central effects of N/OFQ. 
Nociception 
Pronociceptive and antiopioid (supraspinal) I A n t i n o d c e p t i v c (spinal) 1111, 112J 
[3, 90]Pronociccptive (spinal) [110, 1111 I 
Spontoneus locomotor activity __ 
. " tTTT, [Stimulation of locomotion (low doses) (supraspinal) 
Hypolocomotion (supraspinal) [2, 62] | r d a t e d to m x i o l y i l c effect |91] 
Anxiety — : —— 
Anxiolytic- like action (supraspinal) [91] |601 | Anxiogenic-like action (supraspinal) [114] 
Food intake _ _ 
Hyperphagia (supraspinal) [92] _ _ 
Reward and Addiction — 
Abolishes rewarding property of ethanol [94] and morphine [115] 
Suppression of mcthamethamine induced conditioned place preference [96] 
Learning and memory 
Impairs spatial learning and memory retention (supraspinal) [97, 1161 
8. Pharmacology of NOP receptor 
The novel N/OFQ peptide/NOP receptor system is considered to be a 'non-opioid branch of 
the opioid family' due to its close structural and transduction^ similarities and on the other hand 
its pharmacological and functional differences with the classical opioid systems [10]. From the 
numerous modulatory actions of N/OFQ in several neurological pathways, one thing is obvious 
that this novel peptidergic system represents an important molecular target for the development 
of novel therapeutics for several neurological and other pathological conditions [117]. Thus, this 
system is highly attractive for drug design purposes. In fact, there is a tremendous interest from 
pharmaceutical companies in developing both agonists and antagonist non-peptide ligands for 
the NOP receptor as potential drugs for various human disorders [118]. Some of the therapeutic 
applications of NOP receptor agonists, partial agonists and antagonists are summarized in Table 
2. 
Table 2: Potential therapeutic applications of NOP receptor ligands 
AGONISTS PARTIAL AGONISTS ANTAGONISTS 
Anxiolytics 
Stimulants of food intake 
Antitussives 
Anti-epileptics 
Spinal analgesics 
Suppressants of drug abuse 
For management of 
hyponatremia and water 
retention 
Aquaretics (peripherally 
acting) for managements of 
hyponatremia and water 
retention 
Analgesics 
(alone/in combination with opiates) 
Antidepressants 
Anorectics 
Nootropic agents 
Antiparkinson 
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Until now there has been a number of compounds identified that represent useful 
pharmacological tools for clarification of physiological and pathophysiological roles of N/OFQ-
NOP receptor system. Currently available NOP receptor ligands can be classified as the 
following: 
8.1. N/OFQ related peptides 
Peptides that belong to this group are developed by classical structure-activity 
relationship (SAR) studies. Amidation of the C-terminus (N/OFQ-NH2) maintained lull 
potency and activity [59]. Deletion of up to four amino acids from the C-terminus gives 
N/OFQ(l-13) analogues with different activities and receptor affinities depending on the 
C-terminal end chemical function. N/OFQ(l-13)-NH2 becoming the smallest active fragment 
that restores potency and agonist activity comparable with N/OFQ-NH2, whereas the free acid, 
N/OFQ( 1 -13)-OH, has considerably less affinity and potency [59, 119], Replacement of Phe1 by 
Tyr1 resulted in Tyr'-N/OFQ and Tyr1-N/OFQ(l-13)-NH2 that binds also to opioid receptors 
[120, 121], The N-terminal FGGF is essential for the activity and Phe4 is important for receptor 
activation. The replacement of the Phe'-Gly2 amide bond with a pseuodopeptide 
(CH2-NH) bond resulted in the discovery of [PheV(CH2-NH)Gty2]N/OFQ( 1-13)-NH2 
([F/G]N/OFQ( 1-13)-NH2 [121], This ligand was previously purported to be the first NOP 
receptor antagonist, but later on it became evident that this peptide acts as an antagonist, partial 
agonist or even as a full agonist, depending on the tissue preparation [122], Further 
modifications of the N-terminus by transposition of the Phe1 side chain from the a-carbon of 
Phe1 to the N-terminal amino-nitrogen atom led to the design of the first NOP receptor peptide 
antagonist [Nphe,]N/OFQ(l-13)-NH2 [123], Retro-N/OFQ methylester which has an oppositely 
directed structure to that of N/OFQ, is a low potency NOP antagonist [124], 
[Arg14, Lys15]N/OFQ was designed for interaction with more strength and became the first 
peptide agonist more potent than N/OFQ and named as a superagonist [125], 
[Arg14, Lys(DTPA)15]nocicepti n( 1 -17)-NH2 and its cross-linked dimer are synthesized for further 
radiolabelling to get a radiopharmaceutical that can be used diagnostically [126]. Modifications 
on Phe4 residue of N/OFQ(l-13)NH2, revealed that /wrra-substituted electron-withdrawing 
groups such as pF and /?N02 increase the binding affinity and potency and in vivo duration of 
action [127-129], A cyclic peptide having an intramolecular disulphide bridge: 
c[Cys10'14]N/OFQ(l-14)NH2, was reported to be the first conformationally restricted derivative 
among the N/OFQ analogues. This peptide has an agonist activity and may serve as a good 
template for studying the bioactive conformation of N/OFQ [130], Combination of the cyclic 
analog with Nphe1 which previously led to pure antagonism, provided a partial agonist 
c [ N p h e 1 , C y s 1 0 , 1 4 ] N / O F Q ( l - 1 4 ) N H 2 [131], High affinity peptides containing a-helix-promoting 
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conformational constrains, such as [Aib7,Aibu]N/OFQ-NH2 are also reported [132], A series of 
structure-activity studies [133] led to the identification of a very potent antagonist, 
[Nphe1, Arg14, Lys,5]N/OFQ-NH2 (UFP-101) ref.[134], the most potent agonist 
[(pF)Phe4,Arg 14,Lys15]N/OFQ-NH2 (UFP-102) ref.[135] and the most potent partial agonist 
[PheV(CH2-NH)-Gly2,(pF)Phe4,Arg14,Arg15]N/OFQ-NH2 [133], Recently a detailed SAR study 
with combination of different modifications has been performed [136] and a very potent agonist 
[(pF)Phe4,Aib7,Aibu,Arg14,Lysl5]N/OFQ-NH2 and an antagonist (the most potent until now) 
[Nphe1,(pF)Phe4,Aib7,Aibu,Arg14,Lys15]N/OFQ-NH2 was reported [137], 
8.2. Small peptides 
The small peptides in this group are identified by screening of synthetic peptide 
combinatorial libraries. Peptide III-BTD was identified from a combinatorial library of P-turn 
constrained peptides [138], This conformationally restricted peptide is a mixed NOP antagonist / 
opioid agonist [139], Five hexapeptides ( A c - R Y Y R I K - N H 2 , A c - R Y Y R W K - N H 2 , 
A C - R Y Y R W R - N H 2 , A C - R Y Y L W R - N H 2 , A C - R Y Y K W K - N H 2 ) with high affinity and selectivity 
to the NOP receptor were identified from a peptide library containing about 52 millions of 
compounds made considering all the natural amino acids except cysteine [140], Similar to 
[F/G]N/OFQ( 1-13)-NH2, these peptides were partial agonists whose final effects vary from full 
agonist to antagonist depending on the tissue and system used in the study [140-145], These 
hexapeptides, the shortest peptide sequences interacting with the NOP receptor, have been used 
as chemical templates for S A R studies. The head to tail cyclization of A c - R Y Y R W K - N H 2 
produced a drastic decrease in binding affinity [146] while the N-terminal acylation with a 
pentanoyl group [147] or the replacement of the Tyr2,3 residues with (pF)Phe [148] led to the 
discovery of high affinity low efficacy NOP receptor ligands. The N-terminal alkylation of the 
central core Y Y R W with groups bearing a guanidine function generated a NOP receptor agonist 
[149], Modifications on the Trp (W) were also preformed [150], The substitution of the 
C-terminal amide with an alcoholic function produced an antagonist derivative [151] which was 
further shown to behave as a partial agonist [152], Moreover the C-terminal addition of a 
polylysine sequence generated the peptide A c - R Y Y R W K K K K K K K - N H 2 (ZP-120) which 
behaves similarly to the reference compound as a NOP receptor selective partial agonist but 
displays a higher affinity, higher metabolic stability and higher in vivo duration of action [153], 
ZP-120 was patented [154] as a drug candidate (for indications such as aquaresis) especially for 
its selectivity to produce renal but not cardiovascular effects [155, 156], 
8.3. Non-peptide ligands 
The non-peptide ligands are generally discovered via high-throughput screening (UTS) in 
pharmaceutical industry laboratories. Since the NOP receptor represents the non-opioid branch 
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of the opioid family, the search for non-peptide ligands was initiated by examining small-
molecule opiate ligands. Among these compounds: i) o-receptor ligands carbetapentane and 
rimcazole [157]; ii) MOP receptor ligands lofentanil (an anilidopiperidine) and etorphine (an 
oripavine derivative) [158]; iii) anilidopiperidines, morphinans and benzomorphan classes of 
opiate ligands [159]; iv) MOP receptor ligand buprenorphine [160]; 
v) naloxonebenzoylhydrazone (NalBzoH) [161]; vi) the 5-HT partial agonist spiroxatrine These 
compounds have thus far provided useful leads for the design of selective NOP receptor ligands 
(agonist and antagonist). The non-peptide NOP receptor ligands can be broadly divided into five 
structural classes It is noteworthy that many of these ligands were first reported in the patent 
literature (patents from Pfizer, Banyu Pharm., Hoffmann La Roche, EuroCeltique S.A., 
NovoNordisk, Schering, Smith Kline Beecham, Japan Tobacco Inc, Toray Industries, etc). 
However, the biological data of some of them is still not available, thus making it difficult to 
define clearly the structural requirements for NOP receptor affinity and selectivity. 
i) Morphinan-based ligands: Among this group TRK-820 was reported in collaboration with 
Toray Industries, Japan [162]. 
ii) Benzimidazopiperidines: The first non-peptide NOP receptor antagonist was a 
benzimidazolinone, J-l 13397 [163] was patented by Banyu Pharmaceutical Co. [164] and 
followed by several other patents. 
iii) Spiropiperidines: Hoffmann La Roche patented a series of compounds. Among them Ro 65-
6570 and Ro 64-6198 were two of those ligands widely used as pharmacological tools [165]. 
This was followed by other patents such as NovoNordisk (NNC-63-0532) [166], 
iv) Aryl piperidines: Designing compounds in this group led several pharmaceutical companies 
(Schering, Roche etc) to get patents. Recently SB-612111 was patented by GlaxoSmithKline 
[167]. 
v) 4-Aminoquinolines: Japan Tobacco Inc. patented JTC-801 [168], This compound, reported 
to be a competitive antagonist [169], was chosen as the clinical candidate for clinical trials 
for analgesia due to its oral bioavailability profile. Interestingly, the benzimidazolinone 
J-l 13397, also a NOP receptor antagonist, has no analgesic effects per .ve, in similar models 
of nociception. 
Recently a preliminary 2-D pharmacophore useful for understanding the structural 
parameters that play a role in determining the binding, selectivity and the intrinsic activity of 
small-molecule NOP receptor ligands was reported [170], This pharmacophore consists of 3 
elements i) a heterocyclic moiety that has a hydrogen bond acceptor group. This moiety is an 
important determinant of binding affinity and selectivity vs. the opioid receptors, ii) a basic-
nitrogen-containing moiety, iii) a lipophylic moiety on the basic nitrogen that plays a role in 
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optimal binding and in intrinsic activity, thus changing the character from agonist to antagonist. 
For effective NOP receptor agonists and antagonists that can be developed as therapeutics 
ligand-based analysis has to be complemented with the site-directed mutagenesis of the NOP 
receptor as well as the 3-D model of the NOP receptor. Some of the available NOP receptor 
ligands are summarized in Table 3. 
Table 3: Some of the NOP receptor ligands available. 
AGONISTS PARTIAL 
AGONISTS 
ANTAGONISTS 
N
/O
FQ
-R
E
L
A
T
E
D
 P
E
PT
ID
E
 
A
N
A
L
O
G
U
E
S 
1. N/OFQ 12, 3 j 
2. N/OFQ-NH2 [59] 
3. [Tyr']N/OFQ [120] 
4. N/OFQ(l-13)-NH2 [59, 119] 
5. [Arg14,Lys15JN/OFQ [125] 
6. [(pF)Phe4]N/OFQ( 1 -13)-NH2 
[127] 
7. [(pF)Phe4,Aig14,Lys15|N/OFQ-
NH2 (UFT-102) [135] 
8. [(pF)Phe4,Aib7,Aib' Arg14,Lys15] 
N/OFQ-NH, [137] 
1. [PheV(CH2-NH)-
Gly2]N/OFQ(l-13)-
NH2 [121] 
2. [Phe1 \j/(CH2-NH)-
Gly2,(pF)Phe4,Arg14, 
Lys15]N/OFQ-NH2 
[1331 
1. [Nphe']N/OFQ( 1-13)-NH2 
[123] 
2. Retro N/OFQ methylestcr 
[124] 
3. [Nphe1,Arg14,Lysl5]N/OFQ-
NH2 (UFP-101) [134] 
4. [Nphe,,(pF)Phe4,Aib7,Aib11, 
Arg14,Lys15]N/OFQ-NH2 
[137] 
SM
A
L
L
 A
R
T
IF
IC
IA
L
 
PE
PT
ID
E
S 
1. Ac-RYYRWK-NH; 
[140] 
2. Ac-RYYRIK-NH2 
[140] 
3. Ac-RYYRIK-ol 
[151] 
4. Ac-RYYRWKKK 
KKKK-NH2 
(ZP 120) [153] 
1. Peptide-mBTD [138] 
2. Pentanoyl-RYYRWK-NH2 
[147] 
N
O
N
-
PE
PT
ID
E
S 1. Ro 65-6570 [165] 
2. NNC-63-0532 [166] 
3. Ro 64-6198 [165] 
1. NalBzoH [161] 
2. J-l13397 [163] 
3. JTC-801 [168] 
4. SB-612111 [167] 
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n. AIM OF THE STUDIES 
Nociceptin/orphanin FQ (N/OFQ) and its receptor (NOP) constitute a novel peptide-receptor 
system, widely expressed centrally and in the periphery. N/OFQ is involved in pain 
transmission, anxiety and response to stress, learning and memory, food intake, locomotor 
activity. Additionally, N/OFQ controls some functions of the renal, cardiovascular, respiratory 
and gastrointestinal systems. Therefore, it is an emerging molecular target for the development 
of novel therapeutics for several disease states. 
Until now, relatively few ligands (agonists, antagonists and partial agonists) have been 
identified that have high NOP receptor selectivity and potency. Thus, novel ligands are still 
needed both as research tools for further investigations on the N/OFQ - NOP receptor systems 
and as drug prototypes to establish the therapeutic potential of drugs, that selectively interact 
with this receptor. The present study was dedicated to biochemical, functional and 
pharmacological characterization of NOP receptor ligands in particular novel hexapeptide 
derivatives. This study includes the basic characterization of a novel synthetic hexapeptide by in 
vitro and in vivo analyses, and the structure-activity relationship studies performed on this 
compound. 
The main goals of the study were: 
> To identify and characterize putative, selective, potent and stable NOP receptor ligands 
in vitro and in vivo. 
> To investigate the binding properties to the native receptors of rat brain membranes 
and to recombinant human NOP receptors. 
> To examine the post-binding effects (G-protein activation) in the functional biochemical 
[35S]GTPyS binding assay 
> To examine the biological effects in the native receptors localized in N/OFQ sensitive 
tissues that are isolated from mouse vas deferens and mouse colon. 
> To characterize the novel hexapeptide in vivo by i) analgesiometric assay such as tail 
withdrawal, to see its action on supraspinal and spinal level; ii) spontaneous 
locomotor activity test; iii) food intake studies; iv) forced swimming test. 
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III. MATERIAL AND METHODS 
1. Chemicals 
1.1. Radiochemicals 
[/ewcy/-3H]N/OFQ (160 Ci/mmol) was purchased from Amersham, UK. In some of the 
preliminary studies [3H]N/OFQ-NH2 (25 Ci/mmol), [3H]N/OFQ(l-13)-NH2 (30 Ci/mmol), 
[3H]Tyr1-N/OFQ (40 Ci/mmol) were used. These radioligands were radiolabeled by Dr Judit 
Farkas and Dr Géza Tóth. [3H]Naloxone (28 Ci/mmol) was prepared as described [171], 
Guanosine-5'-[Y-35S]-triphosphate (1204 Ci/mmol) was purchased from the Isotope Institute Ltd. 
(Budapest, Hungary) and from Amersham, UK with a specific activity of 1033 Ci/mmol. 
1.2. Peptides 
N/OFQ, N/OFQ(l-13)NH2 were obtained from Bachem, Bubendorf, Switzerland. UFP-101 
([Nphe',Arg14,LysI5]N/OFQ-NH2) was kindly provided by Dr Remo Guerrini, Department of 
Pharmaceutical Sciences and Biotechnology Centre, University of Ferrara, Italy. 
Dr György Orosz, Reanal Finechemical Co. Budapest, kindly provided Tyr'-N/OFQ and 
N/OFQ-NH2. Endomorphin-1 was purchased from Tocris, U.K. Ac-RYYR1 K-NH2, 
Ac-RYYRIK-ol and all the other modified hexapeptides were synthesized accordingly to [151] 
in the laboratory of Dr Anna Magyar (Research Group of Peptide Chemistry, Eötvös Loránd 
University, Budapest, Hungary) using solid-phase peptide synthesis techniques. 
1.3. Other chemicals 
MgCl2, KC1, ethylenediamine-tetraacetic acid (EDTA), polyethyleneimine (PEI), 
Tris-hydroxymethyl-aminomethane, protease-free bovine serum albumin (Protease-free BSA, 
Fraction V), Guanosine 5'-diphospate (GDP), Guanosine-5'-o-(3-thiotriphosphate) GTPyS, 
carbachol were purchased from Sigma-Aldrich (St. Louis, MO, USA). All the tissue culture 
media and supplements were from GIBCO-Invitrogen. Other reagents used in this study were of 
the highest purity available. 
2. Animals 
Inbred Wistar rats (250-300g, Animal House of the Biological Research Centre, Szeged, 
Hungary) were used throughout the in vitro receptor binding part of this study. Rats were kept in 
groups of four, allowed free access to food and water and maintained on a 12/12-h light/dark 
cycle until the time of sacrifice. Animals were treated according to the European Communities 
Council Directives (86/609/ECC) and the Hungarian Act for the Protection of Animals in 
Research (XXVIII.tv. 32.§). 
Male Swiss mice weighing 20-25 g were used throughout the in vitro isolated tissue assays 
and in vivo part of this study (Morini, Reggio Emilia, Italy). Mice were housed in 425 x 266 x 
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155-mm cages (Techniplast, Milan, Italy), eight animals/cage, under standard conditions 
(22°C, 55 % humidity, 12-h light/dark cycle, light on at 7:00 am) with food (MIL, standard diet; 
Morini, Reggio Emilia, Italy) and water ad libitium for at least 3 days before experiments began. 
Each mouse was used only once. In addition, each mouse received only one injection (i.c.v. or 
i t ). Mice were handled according to guidelines published in the European Communities 
Council directives (86/609/EEC) and Italian national regulations (D.L. 116/92). 
Intracerebroventricular injections (i.c.v., injection volume 2 pi) to the left ventricule was 
done according to the procedure described by Laursen and Belknap [172] Briefly, a 27-gauge 
needle attached via a polyethylene tube to a 10-pl Hamilton syringe was used for the injection at 
an angle approximate angle of 45°, at 2 mm lateral to the bregma midline. 
Intrathecal injections (i t., injection volume 5 pi) were adapted according to the method of 
Hylden and Wilcox [173], A 28-gauge stainless steel needle attached to a 50-pl Hamilton 
microsyringe was inserted in the spinal subarachnoid space between the L5 and L6 segments in 
mice. 
3. Isolated tissues and preparation 
In vitro experiments were performed on mouse vas deferens (mVD) and mouse colon (mC). 
On the day of the experiment, the animals were killed by decapitation and the tissues were 
isolated and prepared immediately. The prostatic portion of mouse vas deferens was isolated 
from male Swiss Mice (20-25 g, Morini, Reggio Emilia, Italy) and prepared according to [174], 
The segments, approximately 1 cm length, of mouse colon (Swiss Mice 20-25 g, Morini, Reggio 
Emilia, Italy) were prepared as described in [144] to record the isometric smooth muscle 
contraction. Briefly, the mouse segments of transverse and descending colon (1 cm length) were 
obtained. 
A separate series of experiments were performed in colon tissues taken from 
CD1/C57BL6/J-129 wild type (NOP+/+) and NOP receptor knockout (NOP"'") mice weighing 
20-25 g. These mice were genotyped by PCR. Details of the generation and breeding of mutant 
mice have been published previously [62, 175], 
4. Membrane Preparations 
4.1. Preparation of rat brain membranes 
Crude brain membrane from Wistar rats were prepared as previously described [126, 151]. 
Briefly, rats were decapitated and the brains without cerebellum were quickly removed and 
washed several times with chilled 50 mM Tris-HCl buffer (pH 7.4). Weighed tissues were 
transferred to ice-cold buffer, homogenized using a Braun teflon-glass homogenizer 
(10-15 strokes) and filtered through four layers of gauze to remove large aggregates. The 
homogenate was centrifuged (Sorvall RC5C centrifuge, SS34 rotor) at 40,000 * g for 20 min at 
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4°C and the resulting pellet was resuspended in fresh buffer and incubated for 30 min at 37°C. 
The centrifugation step was repeated, and the final pellet were resuspended in 50 mM Tris-HCl 
buffer (pH 7.4) containing 0.32 M sucrose and stored at -70°C until use. 
4.2. Preparation of CHO-NOPh cells 
Chinese hamster ovary (CHO) cells stably expressing the wild type human nociceptin 
(NOPh) receptor protein was kindly provided by Dr Jean-Claude Meunier, Toulouse, France. 
Cells were cultured in a medium containing Nut Mix F-12 (HAM) with 1-glutamine (G1BCO-
Invitrogen) and 25 mMHepes, 10 % FCS, 100 Ul/ml penicillin, 100 pg/ml streptomycin and 
0.4 mg/ml G418 at 37°C in a humidified atmosphere consisting of 5 % C02 and 95 % air. Cells 
were sub-cultured twice a week. 
Cells were harvested with trypsin solution (0.05 % trypsin, 0.02 % EDTA) in ice cold PBS 
by washing two times, frozen at -70°C for 2 hours to facilitate cell disruption by water 
crystallisation and homogenized in 50 mM Tris-HCl (pH 7.4) buffer with a glass/glass hand 
homogenizer (Wheaton USA). Then centriiuged at 1000 x g for 10 min at 4°C and the collected 
pellets were homogenized in 50 mM Tris-HCl (pH 7.4) buffer with a glass / glass hand 
homogenizer. Homogenates were centriiuged two times at 40,000 x g for 20 min at 4°C. Pellets 
were suspended in Tris-HCl (pH 7.4) buffer and following the protein determination the 
membrane preparation was aliquoted (0.3-0.4 mg/ml protein per series) and stored at -70°C until 
use. Membranes for the GTPyS binding assays were prepared by the same procedure, but the 
pellets were suspended in TEM (50 mM Tris, 1 mM EGTA, 5 mM MgCl2) pH 7.4 buffer And 
membrane fractions were aliquoted (~ 240 pg protein per series = ~ 10 gg protein/sample) and 
stored at -70°C until use. 
5. In vitro biochemical and functional characterization of hexapeptides 
5.1. Radioligand Binding Experiments 
5.1.1. Saturation Binding Experiments 
Aliquots of frozen rat brain membranes were thawed, washed by centrifugation (40 000 * g, 
20 min, 4°C) to remove the sucrose and pellets were suspended in 50 mM Tris-HCl buffer 
(pH 7.4) up to 0.3-0.4 mg/ml protein. Aliquots of CHO-NOPh membranes were thawed and 
homogenised with a syringe and used directly in the binding assay. Membranes were incubated 
with gentle shaking for 1 h, 24°C in a final volume of 1 ml with increasing concentrations of 
[fewcy/-3H]N/OFQ (0.01 - 1 nM) that was prepared in 1 mg/ml protease-free bovine serum 
albumine solution. Non-specific binding was determined in the presence of 1 pM of unlabelled 
N/OFQ. The reaction was terminated by rapid filtration under vacuum (Brandel M24R Cell 
Harvester), and washed three times with 5 ml ice-cold 50 mM Tris-HCl (pH 7.4) buffer through 
Whatman GF/C glass fibers that are presoaked for 30 min in 0.3% Polyethyleneimine (PEI) 
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solution (pH 10). After filtration, filter fibers were dried and bound radioactivity was measured 
in UltimaGold™ scintillation cocktail using Packard Tricarb 2300TR Liquid Scintillation 
Analyzer. Total binding was measured in the presence of the radioligand, non-specific binding 
was determined in the presence of 1 pM unlabeled N/OFQ and subtracted from total binding to 
calculate the specific binding. Protein concentration was measured photometrically by the 
Bradford method with bovine serum albumine as standard [176], 
5.1.2. Competition Binding Experiments 
Aliquots of frozen rat brain membranes were thawed washed by centrifugation 
(40 000 x g, 20 min, 4°C) to remove sucrose and pellets were suspended in 50 mM Tris-HCl 
buffer (pH 7.4) up to 0.3-0.4 mg/ml protein. Aliquots of CHO-NOPh membranes were thawed 
and homogenised with a syringe and used directly in the binding assay. Membranes were 
incubated with gentle shaking for 1 h, 24°C in a final volume of 1 ml with unlabelled 
compounds (10^ to 10"11 M), and ~ 0.05 nM [/ewcy/-3H] N/OFQ which was prepared in 1 mg/ml 
protease-free bovine serum albumin solution. Non-specific binding was determined in the 
presence of 1 pM of unlabelled N/OFQ. The reaction was terminated and bound radioactivity 
was measured in the same way as described above. 
5.1.3. [35S]GTPyS Binding Experiments 
Membranes (~ 10 pg of protein/sample) were incubated at 30°C for 60 min in Tris-EGTA 
buffer (50 mM Tris-HCl, 1 mM EGTA, 3 mM MgCl2, 100 mM NaCl, pH 7.4) containing 
[35S]GTPyS (0.05 nM) and increasing concentrations (10"9-10 5 M) of peptides (for 
concentration response curves) and various concentrations (10 8, 3x10"8, 10"7) of Ac-RYYRIK-ol 
(for Schild plot analyses) tested in the presence of 30 pM GDP in a final volume of 1 ml. Total 
binding was measured in the absence of the tested compound, non-specific binding was 
determined in the presence of 10 pM unlabeled GTPyS and subtracted from total binding to 
calculate the specific binding. The reaction was started by addition of [35S]GTPyS and 
terminated by filtrating the samples through Whatman GF/B glass fiber filters. Filters were 
washed three times with ice-cold 50 mM Tris-HCl buffer (pH 7.4) using Brandel M24R Cell 
Harvester, then dried. Bound radioactivity was detected in UltimaGold™ scintillation cocktail 
(Packard). [35S]GTPyS binding experiments were performed in triplicates and repeated at least 
three times. 
5.2. Isolated tissue assays 
5.2.1. Mouse vas deferens bioassay 
The mouse vas deferens tissues were suspended in 5 ml organ bath containing Mg2+ free, 
and 1.8 mM CaCl2 containing Krebs buffer (in mM: 118.1 NaCl, 4.7 KC1, 2.5 CaCl2.2H20, 
1.2 KH2P04, 25 NaHCOa, and 5 Glucose) at 33°C and incessantly gassed with 5% C02 and 
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95% 0 2 A resting tension of 0.3 g was applied. The mVD tissues were continuously stimulated 
through two platinum ring electrodes with supramaximal voltage rectangular pulses of 1 ms 
duration and 0.05 Hz frequency. Electrically evoked contractions (twitches) were measured 
isotonically with a strain gauge transducer (Basile 7006) and recorded with the PC based 
acquisition system Autotrace 2.2 (RCS, Florence, Italy). Following an equilibration period of 
about 60 min, the contractions induced by electrical field stimulation were stable subsequently 
the cumulative concentration-response curves to N/OFQ were performed (0.5 log unit steps) in 
the absence or in the presence (30 min preincubation time) of hexapeptides. For Schild plot 
analyses increasing concentrations of Ac-RYYRIK-ol (10 - 1000 nM) was used. 
5.2.2. Mouse colon Assay 
Segments of mouse colon were mounted vertically under 1 g tension in an organ bath 
(10 ml) containing Krebs buffer at 37°C and continuously gassed with 5% C02 and 95% 02. 
Tissues were equilibrated for 60 min with washing every 10 min. For recording the maximal 
contractile response of the tissues 100 pM carbachol (carbamylcholine chloride) was used. The 
concentration-response relationships were determined non-cumulatively by adding different 
concentrations of peptides to the bath every 20 min followed by washing. 
6. In vivo pharmacological characterization of hexapeptides 
6.1. Tail Withdrawal Assay 
All experiments were started at 10.00 a.m. and performed according to the procedures 
previously described [177], Briefly, the mice were placed in a holder and the distal half of the 
tail was immersed in water at 48°C. Withdrawal latency time was measured by an experienced 
observer blind to the drug treatment. A cut off time of 20 s was chosen to avoid tissue damage. 
Four mice were randomly assigned to each experimental group and the experiment was repeated 
at least 3 times. Tail withdrawal latency was determined immediately before and at 5, 15, 30, 
and 60 min after i.e. v. or i.t. injection of saline (control), and Ac-RYYRIK-ol (0.01 - 1 nmol). 
6.2. Locomotor Activity Assay 
Experiments were performed starting at 10.00 am, following the procedures previously 
described [178], Briefly, the mice were routinely tested 5 min after i.c.v. injection of 
Ac-RYYRIK-ol (0.01 - 1 nmol). Locomotor activity was assessed using Basle activity cages, 
which consist of a four-channel resistance detector circuit which converts the bridges "broken" 
by the animal paws into pulses that are summed up by an electronic counter every 5 min. Total 
number of impulses were recorded every 5 min for 60 min. Mice were not accustomed to the 
cages before drug treatment and the experiment was performed in a quiet and dimly illuminated 
room. Four mice were randomly assigned to each experimental group and the experiment was 
repeated at least 3 times. 
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6.3. Food Intake Assay 
The experiments were carried in freely feeding and drinking mice. The experiments took 
place at 10:00 a.m. Mice were individually housed in a cage and saline or Ac-RYYRIK-ol 
(0.001 - 0.1 nmol) were injected i.e.v. Food intake was measured at 30 and 60 min following 
drug injection. Food intake was expressed as g/kg of body weight. 
6.4. Forced Swimming Test 
Experiments were performed following the procedures previously described [175], The test 
consists in placing mice, individually, in a Plexiglás cylinders (18.5 cm high, 12.5 cm diameter, 
water 13.5 cm deep) partially filled with water (24-26 °C), for two swimming sessions: an initial 
15-min training session, which was followed by a 5-min test session 24 h later. The time each 
animal remained immobile (immobility time) during the 5-min test session was recorded. 
Animals were judged immobile when they ceased struggling/swimming and remained floating 
motionless in the water, making only those movements necessary to keep their heads above the 
water line. At the end of each swimming session, the animal was removed from the cylinder, 
dried with paper towels, placed in an individual cage for rest and recovered over 15 min, and 
then returned to its collective home cage. Ac-RYYRIK-ol (0.001 - 0.1 nmol) was injected i.c.v 
5 min before the test. In some experiments, Ac-RYYRIK-ol 0.1 nmol and UFP-101 10 nmol 
was co-injected i.c.v. 5 min before the test 
7. Data Analysis and Terminology 
All data are expressed as means ± standard error of the mean (S.E.M.) of at least 
3 experiments. All the binding experiments were performed in duplicates and the [35S]GTPyS 
binding assays were performed in triplicates. Data was analyzed by GraphPad Prism (version 
3.0 and 4.0 San Diego, CA, USA). Hyperbolic saturation binding curves were fitted by non-
linear regression using one-site binding model and equilibrium dissociation constant (Kd) and 
maximal number of binding sites ( I W ) were calculated. Sigmoid displacement curves were 
also analysed to yield affinity values expressed as I C 5 0 by non-linear regression using the one-
site competition fitting option. The equilibrium inhibition constant (K,) was calculated according 
to the Cheng-Prusoff equation: K¡ = IC5o/(l+[L]/Kd) [179] where [L] designates the labelled 
ligand concentration and I C 5 0 is the concentration of the competitor producing 50 % 
displacement. pK¡ is the antilogarithm of the K¡ values obtained after the calculations. 
[35S]GTPyS binding data were analysed by sigmoid dose-response curve fit option of Prism 3 .0. 
Stimulation is given as percent of the specific [35S]GTPyS binding observed in the absence of 
receptor ligands (basal activity). Agonist potencies were expressed as pEC50, which is the 
negative logarithm to base 10 of the agonist molar concentration that produces 50% of the 
maximal possible effect of that agonist. The E ^ is the maximal effect that an agonist can elicit 
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in a given tissue/preparation. E^x of agonists is expressed as the maximal stimulation of 
[35S]GTPyS over the basal (for [35S]GTPyS binding), % of inhibition of the control twitch (for 
the electrically stimulated vas deferens), % of the contraction elicited by 100 pM carbachol (for 
mouse colon data). Antagonist potencies were expressed as pA2 which is the negative logarithm 
to the base 10 of the antagonist molar concentration that makes it necessary to double the 
agonist concentration to elicit the original submaximal response [180], pA2 values were 
calculated by Schild's linear regression, that correlates the log of concentrations of antagonist 
(x-axis) to the log of (CR-1) (y-axis), where CR is the ratio between the EC5o (nM) values of the 
agonist in the presence and absence of antagonist. If the slope of the regression line is not 
significantly different from the unity, the value of x for y = 0 represents the pA2 value, and the 
slope not significantly different from the unity refers to competitive antagonism. When one 
single concentration of antagonist is used, the antagonist potency was indicated as pKe value 
and calculated with Gaddum Schild Equation (pA2 = -log{(CR-l)/[Antagonist]}). 
In vivo data have been statistically analyzed with the Student's /-test or one way ANOVA 
followed by the Dunnett test, as specified in figure legends; p values less than 0.05 were 
considered statistically significant. In vivo data from studies in mice were analyzed as follows: 
for tail withdrawal experiments raw data were converted to the area under the time versus tail 
withdrawal latency curve (AUC min s"1) as described by [181]. The AUC data for the interval of 
time (0-60 min) was calculated and these values were used for statistical analysis. Locomotor 
activity data were statistically analyzed using the data expressed as cumulative impulses over 
the 60 min observation period. 
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IV. RESULTS 
1. In vitro biochemical and functional characterization of hexapeptides 
In this part of the study in vitro biochemical and functional characterization of newly 
synthesized series of NOP receptor ligands (summarized in Table 4) are described. These 
studies include receptor binding, functional [35S]GTPyS binding and isolated tissue assays. 
Table 4: Compounds used in this study. 
No Amino Acid Sequence Structure / Abbreviated Name 
1 Phe-Gly-Gly-Phe-Thr-Gly-AIa-Arg-Lys-Ser-Ala-Arg-Lys-Leu-Ala-Asn-Gln 
f g g f t g a r k s a r k l a n q 
(N/OFQ) 
2 
Phe-Gly-Gly-Phe-Thr-Gly-Ala-Arg-Lys-Ser-Ala-Arg-
Lys-Leu-Ala-Asn-Gln-NH2 
f g g f t g a r k s a r k l a n q - n h 2 
(N/OFQ-NH2) 
3 Tyr'-Gly-Gly-Phe-Thr-Gly-Ala-Arg-Lys-Ser-Ala-Arg-Lys-Leu-Ala-Asn-Gln 
y g g f t g a r k s a r k l a n q 
(Tyr1-N/OFQ) 
4 Phe-Gly-Gly-Phe-Thr-GIy-Ala-Arg-Lys-Ser-Ala-Arg-Lys-NH2 
f g g f t g a r k s a r k - n h 2 
(N/OFQ(l-13)NH2) 
5 [Nphe1,ArgI4,Lys15]N/OFQ-NH2 f g g f t g a r k s a r k r k n q - n h 2 (UFP-101) 
6 Acetyl-Arg-Tyr-Tyr-Arg-Ileu-Lys-NH2 aC-RYYRIK-nh2 "parent compound" 
7 Acetyl -Arg-Tyr-Tyr-Arg-Ileu-Lys-ol Ac-RYYRIK-ol 
8 Acetyl -Cit-Tyr-Tyr-Cit-Ileu-Lys-NH2 Ac-Cit-YY-Cit-IK-NH2 
9 Acetyl -Cit-Tyr-Tyr-Arg-Ileu-Lys-NH2 Ac-Cit-yyrik-NH2 
10 Acetyl -Arg-Tyr-Tyr-Cit-I leu-Lys-NH2 Ac-RYY-Cit-IK-NH2 
11 Acetyl -Cit-Tyr-Tyr-Cit-Ileu-Lys-ol Ac-Cit-YY-Cit-IK-ol 
12 Acetyl -Cit-Tyr-Tyr-Arg-Ileu-Lys-ol Ac-Cit-YYRIK-ol 
13 Acetyl -Arg-Tyr-Tyr-Cit-Ileu-Lys-ol Ac-RYY-Cit-IK-ol 
14 Chloro-acetyl -Arg-Tyr-Tyr-Arg-Ileu-Lys-ol ClAc-RYYRIK-ol 
15 Benzoyl-Arg-Tyr-Tyr-Arg-Ileu-Lys-ol Bz-RYYRIK-ol 
16 Formyl-Arg-Tyr-Tyr-Arg-Ileu-Lys-ol For-RYYRIK-ol 
17 Pivaloyl-Arg-Tyr-Tyr-Arg-Ileu-Lys-ol Piv-RYYRIK-ol 
18 H-Arg-Tyr-Tyr-Arg-Ileu-Lys-ol H-RYYRIK-oI 
19 Mesyl-Arg-Tyr-Tyr-Arg-Ileu-Lys-ol Ms-RYYRIK-ol 
y!»»® 
1.1. Radioligand Binding Experiments 
1.1.1. Saturation Binding Experiments 
Saturation binding experiments measure specific binding at equilibrium at various 
concentrations (often 6-12) of the radioligand to determine receptor number and affinity. 
Specific binding is plotted against the concentration of the radioligand. The linear 
transformation of the saturation curve "Scatchard plot" [182] was used to calculate the Bmax 
(maximal number of binding sites) and K^ (equilibrium dissociation constant) values. The 
identification of the dissociation constant (Kd) of [/ewcy/-3H]N/OFQ is crucial for further 
characterization of the hexapeptides (i.e., to determine the inhibitory constant, K; values of the 
hexapeptides). 
In the equilibrium saturation experiments, various concentrations (0.01-1 nM) of the 
radioligand were incubated with the membrane. Binding of [/ewcy/-3H]N/OFQ to rat brain 
membranes (Fig. 5 left panel) and CHO-NOPh (Fig. 5 right panel) at 25°C was saturable and of 
high affinity. The equilibrium dissociation constant (Kd) and the maximal number of binding 
sites (Bmax) were calculated by nonlinear regression analysis of the saturation binding data. 
Fig. 5: Saturation binding curves with [/<?wcy/-3H]N/OFQ and inserted scathard plots. Left 
panel: [/ewcy/-3H]N/OFQ binding on native NOP receptors of rat brain membrain. Right panel: 
[/e«cy/-3H]N/OFQ binding on CHO-NOPh. Data is representative of at least 3 experiments. 
The results showed the existence of a single binding component with Kd values of 
0.22 ± 0.04 nM and 0.105 ± 0.01 nM and the maximal binding capacity (Bmax) values were 
604.75 ± 17.05 fmol/mg and 290.4 ± 12.03 fmol/mg protein for CHO-NOPh and rat brain 
membranes, respectively. The Bniax value of CHO-NOPh is twice as much as that of rat brain, 
which is a significant difference (p<0.05, unpaired t-test). However the IQ values were not 
significantly different from each other (p>0.05, unpaired t-test). Non-specific binding of 
[fewcy/-3H]N/OFQ to the membrane preparations was less than 10 % of total binding at a 
RAT BRAIN NEMBRANES CHO-NOPh MEMBRANES 
0.0 0.2 0.4 0.6 0.8 1.0 1.2 
[Leucyl-3H]N/OFQ, nM 
0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 
[Leucyl-3H]N/OFQ, nM 
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radioligand concentration close to the Kj values. These results are in good agreement with the 
literature data [183], Until now, there is a disparity among the reported fQ and the B ^ values 
calculated not only from saturation binding experiments but also from the homologous 
displacement binding experiments. Furthermore no complete correlation can be established 
between affinities observed and radioligand, or receptor source used [183], 
1.1.2. Competition Binding Experiments 
Competitive or displacement binding experiments measure the binding of a single 
concentration of labelled ligand in the presence of various concentrations of unlabelled ligand to 
determine the equilibrium inhibitory constant Ki, affinity of the drug to the receptor. 
Competition binding experiments were used to determine the ability of the new peptides 
competing for the NOP receptor binding sites. 
Receptor binding experiments were performed with [/e«cy/-3H]N/OFQ on membranes from 
rat brains (Fig. 6 left panel) and cells expressing human NOP receptor (Fig. 6 right panel). In 
this figure the hexapeptides are shown in two panels to avoid the crowd on the graphic. 
RAT BRAIN MEMBRANES CHO-NOPh MEMBRANES 
125-, 
k>g[ligand], M 
• N/OFQ 
• Ac-RYYRIK-ol 
. Ac-RYYRIK-NH2 
• Ac-RYY-Cit-IK-ol 
. Ac-RYY-C*-IK-NH2 
log [ligand], M 
» Ac-RYYRIK-ol 
' CIAc-RYYRIK-ol 
• Bz-RYYRIK-ol 
• For-RYYRIK-ol 
• Piv-RYYRIK-ol 
« H-RYYRIK-ol 
» Ms-RYYRIK-ol 
Fig. 6: Competition binding curves with [/ei/cj7-3H]N/OFQ. Left panel: displacement curves for 
C-terminally modified and Arg/Cit replaced ligands on native NOP receptors of rat brain 
membrain. Right panel: displacement curves for N-terminally modified ligands on CHO-NOPh. 
Hexapeptides are shown in rank order of affinity. Points indicate means and vertical lines the 
S.E.M. of at least 3 experiments. 
All the compounds were effectively competed [/ewcy/-3H]N/OFQ in a concentration 
dependent manner. Heterologous competition curves for each compound were satisfactorily 
fitted according to the single-site binding model. The pK, values are shown in Table 5. Among 
the hexapeptides Ac-RYYRIK-ol, the hexapeptide alcohol, showed the highest affinity towards 
the NOP receptor (pK, = 9.10 and 9.39 M, rat brain and CHO-NOPh, respectively). 
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nh— c = nh, o = c — nh, Replacement of the arginine residue 
nh Peptidyi nh with citrulline (an uncharged a-amino 
; arginine I . . . . 
ch, deiminase ch acid structurally similar to arginine shown 
; (pad) i , 
ch _ ch. in Fig. 7) at 1st and/or 4th position 
ch, Ca' ch, indicated that the positively charged 
—nh—ch—c— —nh—ch —c— arginine residue at 1st position is crucial 
|| i 
o ° for the hexapeptide structure. When the 
Ar&mne Citru"ine positively charged arginine residue was 
, . ... replaced with citrulline the binding 
Fig. 7: Structure of arginine and citrulline. 
affinity was lost regardless of the 
C-terminal modification. However, the lower but still acceptable binding affinities show that the 
citrulline replacement at the 4th position was more tolerable. The N-terminal modifications led to 
compounds having lower affinities to the NOP receptor. All hexapeptides were also tested for 
competing against [3H]naloxone, to estimate their affinity towards opioid binding sites, if any. 
Only very weak binding affinities were observed by displacing [3H]naloxone at very high 
peptide concentrations (figure not shown). Thus, no further experiments were performed with 
labelled opioid ligands (MOP, DOP, KOP receptor radioligands) for testing their selectivity. 
Table 5: Displacement binding data of the hexapeptides in membranes from rats and 
Chinese Hamster Ovary Cells expressing human NOP receptor. 
PEPTIDES pKi± S.E.M 
RAT BRAIN CHO-NOPh 
N/OFQ 9.29 ± 0.06 9.20 ± 0.06 
N/OFQ(l-13)NH2 9.37 ±0.071 9.71 ± 0.09 
AC-RYYRIK-NH2" 8.80 ±0.04 9.16 ±0.04 
Ac-RYYRIK-ol 9.10 ±0.04 9.39 ± 0.06 
Ac-Cit-YY-Cit-IK-NH2 <5 <5 
Ac-Cit-YYRIK-NH2 <5 <5 
Ac-RYY-Cit-IK-NH2 6.63 ± 0.2 6.32 ±0.12 
Ac-Cit-YY-Cit-IK-ol <5 <5 
Ac-Cit-YYRIK-ol <5 <5 
Ac-RYY-Cit-IK-ol 7.30 ±0.13 7.39 ±0.15 
CIAc-RYYRJK-ol 8.35 ±0.29 8.86 ± 0.08 
Bz-RYYRlK-ol 7.43 ± 0.26 7.78 ± 0.23 
For-RYYRIK-ol 8.00 ±0.11 7.93 ±0.17 
Piv-RYYRIK-ol 7.63 ±0.31 7.52 ±0.12 
H-RYYRIK-ol 6.39 ± 0.06 6.81 ±0.05 
Ms-RYYREK-ol 6.78 ±0.13 6.80 ±0.18 
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1.1.3. (35S]GTPyS Binding Experiments 
This test is a widely used functional biochemical assay for determining the pharmacological 
property of ligands in vitro. GPCRs couple to Ga,/0, Go*, Ga*,, however, the G, coupling is the 
most abundant. In the inactive state of the receptor the membrane bound G-protein exists as 
Ga(GDP)Py. Activation of receptor by an agonist leads to the dissociation of GDP from Ga, 
allowing endogenous GTP to bind to Ga. Consequently, Ga-GTP and GPy subunits are 
dissociated and are able to interact with the effector systems. The G-protein heterotrimer is 
reformed by the GTPase activity of the Ga subunit, forming Ga-GDP and allowing Ga and GPy to 
re-combine. Using the [35S]GTPyS binding assay is mostly suitable for receptors coupled to the 
abundant GtXj/0 proteins and measures the functional consequence of receptor occupancy by 
agonists at one of the earliest receptor-mediated events. This process can be easily monitored by 
using a non-hydrolysable analogue of GTP that contains a y-thiophosphate bond ([35S]GTPyS). 
Since heterotrimer formation will be delayed, the [35S]GTPyS will accumulate in the membrane 
and thus can be measured by counting the amount of [35S]-label incorporated [184], 
The pharmacological parameters like potency (ECso) and efficacy (Emax) as well as the 
relative intrinsic activities of the hexapeptides were determined on membranes from rat brains 
and CHO cells expressing human NOP receptor. These results were compared with those of 
N/OFQ, which is the reference full agonist at the NOP receptor. All the hexapeptides displayed 
weak to moderate concentration dependent stimulations of the G-proteins on the rat brain 
membranes, indicating their partial agonist properties. The weak intrinsic efficacy observed in 
native receptors of rat brain (Fig. 8 left panel) was clearly amplified at the recombinant human 
NOP receptors therefore all the hexapeptides exerted agonist to partial agonist effects (Fig. 8 
right panel). Experimental data of N/OFQ and the hexapeptides were clearly fitted with 
monophasic sigmoid dose-response curves (Fig. 8 ). In this figure, the C-terminally modified 
and Arg/Cit replaced hexapeptides, and the N-terminally modified hexapeptides shown in two 
panels in order to avoid the crowd on the graphic. The maximal stimulation percentage values 
(Emax) and the potency (pECso) of the ligands are summarized in Table 6. 
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Fig. 8: [35S]GTPyS binding experiments. Left panel: stimulation of G-protein activation by 
N/OFQ analogs, C-terminally modified and Arg/Cit replaced ligands on native NOP receptors of 
rat brain membrain. Right panel: stimulation of G-protein activation by N-terminally modified 
ligands on CHO-NOPh Points indicate means and vertical lines the S.E.M. of at least 
3 experiments performed in triplicates. 
Table 6: [35S]GTPyS binding data, the stimulation of G-proteins by the hexapeptides in 
native NOP receptors of rat brain and recombinant human NOP receptor. The pECso values are 
not determined due to the shallow concentration-response curves (nd referes to not determined). 
PEPTIDES 
RAT BRAIN CHO-NOPh CELL 
Emu 
(Stim. %) 
pECso ± 
S.E.M 
Emax 
(Stim. %) 
pECso ± 
S.E.M 
N/OFQ 162.9 ± 1.81 6.60 ±0.14 669.7 ± 66.03 8.76 ± 0.09 
AC-RYYRIK-NH2 115.5± 1.7 nd 517.3 ±97.21 8.36 ±0.18 
Ac-RYYRIK-ol 122.7 ±4.66 nd 540.9 ±82.70 8.52 ±0.05 
Ac-RYY-Cit-IK-NH2 127.7 ±3.30 nd 427.1 ±40.01 6.81 ±0.04 
Ac-RYY-Cit-IK-ol 107.0 ±9.04 nd 331.5 ±3.41 6.86 ± 0.23 
CIAc-RYYRIK-ol 112.4 ±4.56 nd 330.9 ±25.43 8.43 ± 0.04 
Bz-RYYRIK-ol 100.8 ±4.79 nd 223.5 ± 5.252 7.06 ± 0.22 
For-RYYRIK-ol 129.2 ±5.63 nd 356.1 ±48.48 7.20 ±0.14 
Piv-RYYRIK-ol 108.9 ±2.56 nd 237.9 ±20.71 7.19 ±0.07 
H-RYYRIK-ol 101.7 ±0.38 nd 201.2 ± 16.06 6.40 ±0.14 
Ms-RYYRIK-ol 112.2 ± 1.44 nd 325.3 ±25.32 6.55 ±0.18 
Due to their weak intrinsic activities seen in the native NOP receptors of the rat brain, these 
hexapeptides were tested to antagonise the N/OFQ stimulated G-protein activation. At 1 pM 
effective concentration the hexapeptides could inhibit the N/OFQ stimulated G-protein 
activation in rat brain membranes with low antagonist potencies (pA2< 7.0, except for 
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Ac-RYYRIK-ol, data not shown). Among the hexapeptides, Ac-RYYRIK-ol showed the highest 
affinity, so it was investigated further. Increasing concentrations of Ac-RYYRIK-ol was used to 
inhibit the N/OFQ stimulated G-protein activation. Ac-RYYRIK-ol shifted the concentration 
response curve of N/OFQ to the right in a concentration dependent manner (Fig. 9 left panel). 
The Schild plot analyses (r2 = 1, slope not significantly different from unity) yielded a pA2 value 
of 8.67 (Fig. 9 right panel), thus Ac-RYYRIK-ol behaved as a highly potent competitive 
antagonist in the native NOP receptors of the rat brain. 
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Fig. 9: Stimulation of [35S]GTPyS binding on native NOP receptors of rat brain membranes. 
Left panel: Concentration response curve of N/OFQ obtained in the absence (control) and 
presence of increasing concentrations of Ac-RYYRIK-ol (10-100 nM). Right panel: 
corresponding Schild plot. Points indicate the means and vertical lines the S.E.M of at least 3 
separate experiments that were performed in triplicates. CR: the ratio between the EC50 (nM) 
values of the agonist in the presence and absence of antagonist. 
However, when these ligands were tested to stimulate the G-protein activation on 
CHO-NOPh cells, they all turned out to be agonists or more evidently partial agonists. The 
indistinguishable intrinsic activities of some of the hexapeptides were amplified by using CHO 
cells expressing human NOP receptors with a binding capacity of 604.75 fmol/mg (twice as 
much as that of native receptors of rat brain), and these ligands showed pharmacological 
properties changing from full agonist to partial agonists (figure not shown, see Table 6 for 
pEC50 and I w values). Not surprisingly, the purported antagonist Ac-RYYRIK-ol behaved 
almost as the full agonist N/OFQ with a similar potency and efficacy. The well known NOP 
receptor antagonist, the peptide UFP-101 ref. [134] showed almost no intrinsic agonist activity 
when used in these cells to stimulate G-protein activation. (Fig. 10). 
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[35S]GTPyS binding on CHO cells 
expressing NOPh receptors. 
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1.2. Isolated Tissue Assays 
1.2.1. Mouse vas deferens Bioassay 
The longitudinal muscle of the guinea pig ileum (GPI) [185, 186] and the smooth muscle 
preparation of the mouse vas deferens (mVD) [186, 187] are widely used for in vitro 
pharmacological characterization (efficacy, potency and selectivity) of the opioid receptor 
agonists and antagonists. GPI is known to be rich in p- and particularly K-opioid receptors 
(MOP and KOP), while mVD contains all three opioid receptors, however it is mostly sensitive 
to 8-opioid receptor (DOP) [188], N/OFQ was shown to inhibit the electrically stimulated 
contractions both in mVD [174, 188, 189] and in GPI [174] [188], In these preparations, the 
twitch response to the electric field stimulation due to nerve activation and subsequent release of 
neurotransmitter occurs (that is blocked by tetrodotoxin, TTX). The contractions of mouse and 
rat vas deferens derive largely from the release of noradrenaline from the sympathetic nerves, 
since they are blocked by ai-adrenergic receptor antagonist prazosin. In the guinea pig ileum, 
atropine and tetrodotoxin sensitive contractions derive from the release of acetylcholine from 
cholinergic terminals of the myenteric plexus. 
In the mouse vas deferens, N/OFQ inhibited the twitch response to electrical field 
stimulation in a concentration dependent manner showing an Emax of 90 ± 5% and a pECso of 
7.60 (Fig 11 left panel). In this preparation, Ac-RYYRIK-ol was completely inactive at 10 and 
100 nM while at 1 pM it produced a slight inhibition of the electrically induced twitch in 5 out 
of 8 tissues. Ac-RYYRIK-ol tested over the concentration range of 10 - 1000 nM shifted the 
concentration response curve of N/OFQ to the right in a concentration dependent manner. 
Curves obtained in the presence of Ac-RYYRIK-ol were parallel to the control and reached 
similar maximal effects even in the presence of the highest concentration of compound (Fig. 11 
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left panel). The corresponding Schild plot was linear (r2=0.99) with a slope not significantly 
different from unity yielding a pA2 value of 8.46 (Fig. 11 right panel). 
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Fig. 11: Effects of N/OFQ and Ac-RYYRIK-ol in the electrically stimulated mouse vas 
deferens. Left panel: concentration response curves to N/OFQ obtained in the absence (control) 
and presence of increasing concentrations of Ac-RYYRIK-ol (10 - 1000 nM). Right panel: 
Corresponding Schild plot. Points indicate the means and vertical lines the S.E.M. of at least 4 
separate experiments. 
N-terminally modified and Arg-Cit replaced hexapeptides were also tested in mVD. In an 
attempt to determine the agonistic activity, the structurally modified hexapeptides were tested 
alone for their ability to inhibit the twitch response to the electric stimulation. A slight inhibition 
(<50%) was recorded only at high concentrations (i.e., 1 pM). Thus, the hexapeptides tested 
were indicated as 'variable agonist effect' in the Table 7. On the other hand, these compounds 
could antagonize the effect of N/OFQ on the mVD at 1 pM concentration or even at 100 nM in 
the case of ClAc-RYYRIK-ol. Table 7 shows the antagonist potencies (pKB) of the modified 
hexapeptides. 
Table 7: Effects of the hexapeptides on the electrically stimulated mouse vas deferens. 
PEPTIDES 
Agonist Antagonist 
pECso ± S.E.M Emax (Inh. %) pKB ± S.E.M 
N/OFQ 7.6 ±0.05 90 ± 5 % / 
Ac-RYY-Cit-IK-NH2 variable agonist effect 6.34 ±0.21 
Ac-RYY-Cit-EK-ol variable agonist effect 6.56 ±0.14 
ClAc-RYYRIK-ol variable agonist effect 8.22 ±0.11 
Bz-RYYRIK-ol variable agonist effect 6.05 ±0.3 
Piv-RYYREK-oI variable agonist effect 7.02 ± 0.26 
H-RYYRIK-ol variable agonist effect 6.05 ± 0.25 
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1.2.2. Mouse colon Bioassay 
Principally MOP and KOP receptors are highly expressed in the myenteric plexus and nerve 
terminals in colon tissues [190], Despite their stimulatory action on colonic contractions, opioids 
slow the colonic transit [191]. Although N/OFQ inhibits the neurotransmitter release similarly to 
opioids, it has been shown that N/OFQ preferentially stimulates muscle contraction in the rat 
colon in the upper GI tract without affecting motility, but enhancing colonic transit in vitro [98, 
192] and in vivo [193], N/OFQ induced contractions are mediated through a purinergic, non 
opioid mediated mechanism [194], 
In the isolated mouse colon, N/OFQ evoked concentration dependent contractile effects 
showing a pECso of 8.80 and an Emax of 32.2 ± 1.2 %. This effect was mimicked by 
Ac-RYYRIK-ol which displayed similar maximal effects (28.4 ± 1.3 %) but with 2 fold higher 
potency (pECso 9.09) (Fig. 12 left panel). The effects of Ac-RYYRIK-ol were also investigated 
in colon tissues taken from NOPT/+ and NOP"'" mice. 100 nM of N/OFQ and Ac-RYYRIK-ol 
produced a contraction of colon tissues of NOP' ' mice amounting to 37± 7% and 32 ± 5% of 
contraction induced by 100 pM of carbachol, respectively. These two peptides were found 
completely inactive when tested in tissues taken from NOP"'" mice (Fig. 12 right panel). On the 
contrary, the selective MOP receptor agonist endomorphin-1 (tested at 1 pM) produced similar 
contractile effects in tissues from NOP1/1 and NOP"'" animals (Fig. 12, right panel). Thus, these 
results show the NOP receptor selectivity of the action of N/OFQ and Ac-RYYRIK-ol in the 
mouse colon. 
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Fig. 12: Effects of N/OFQ and Ac-RYYRIK-ol in the isolated mouse colon. Left panel: 
concentration response curve to N/OFQ and Ac-RYYRIK-ol in tissues taken from male Swiss 
mice. Right panel: effect of single concentrations of N/OFQ, Ac-RYYRIK-ol, and EM-1 on 
mouse colon tissues taken from NOP4 4 and NOP" " mice. Points indicate the means and vertical 
lines the S.E.M. of at least 3 separate experiments. 
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2. In vivo pharmacological characterization of hexapeptide alcohol 
The hexapeptide alcohol, Ac-RYYRIK-ol, appeared to be a potent and high affinity n o p 
receptor ligand. This interesting compound was aimed to be characterized further, particularly in 
the in vivo assays: i) to estimate if the novel compound is efficient in vivo, and if so, ii) to 
determine what kind of pharmacological behaviour the novel compound has, iii) if the behaviour 
changes due to the different ways of administration, or if it differs in peripheral/central level. In 
this part briefly the pharmacological assay results are summarized and compared with the results 
obtained by N/OFQ and analogues from the literature data. 
2.1. Tail withdrawal assay 
I.c.v. injection of 0.01 nmol of Ac-RYYRIK-ol in mice did not induce any effect on gross 
behaviour. In contrast, mice treated with 0.1 and particularly with 1 nmol Ac-RYYRIK-ol 
displayed a decrease in locomotor activity, ataxia and loss of the righting reflex, similarly to 
what was observed and reported by various groups after the i.c.v. injection of high doses 
(> 1 nmol) of N/OFQ [2, 177, 178], However, whilst the effects of N/OFQ on gross behaviour 
appeared immediately after i.c.v. injection, those produced by Ac-RYYRIK-ol were slower to 
develop becoming evident only after 15-20 min. No effects were observed in the gross 
behaviour of the mice after i t. injection of Ac-RYYRIK-ol. 
In the tail withdrawal assay, the i.c.v. injection of saline did not modify tail withdrawal 
latencies, which remained stable around 5 s for the time course of the experiments 
(Fig. 13, left panel). Ac-RYYRIK-ol at the dose of 0.01 nmol failed to alter the animal response 
while at 0.1 and 1 nmol the compound produced a reduction of tail withdrawal latencies, which 
peaked at 5-15 min and returned to control values after 30 min from the i.c.v. injection. 
However, AUC (0-60 min) data for 0.1 (256 ± 48) and 1 nmol (248 ± 77) Ac-RYYRIK-ol 
compared to saline (309 ± 19) failed to reach statistical significance (Fig. 13 left panel). 
In the same assay, the i.t. injection of saline did not modify tail withdrawal latencies 
(Fig. 13, right panel). The i.t. administration of Ac-RYYRIK-ol at the dose of 0.01 nmol 
produced a slight increase in tail withdrawal latencies. At higher doses (i.e., 0.1 and 1 nmol) the 
peptide evoked a clear and robust antinociceptive effect which peaked at 15 min and did not 
return to control values even after 60 min (Fig. 13 right panel). AUC(0-60) data for 0.1 nmol 
556 ± 44 and 1 nmol 518 ± 46 Ac-RYYRIK-ol compared to saline 346 ± 23 is statistically 
significantly p<0.05 according to ANOVA followed by the Dunnett's test. 
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Fig. 13: Effects of Ac-RYYRIK-ol in the mouse tail withdrawal assay. Left panel: dose 
response curve to Ac-RYYRIK-ol (0.01 - 1 nmol) injected i.c.v. (AUC(0-60): saline 309 ± 19; 
0.01 nmol 289 ± 25; 0.1 nmol 256 ± 48; 1 nmol 248 ± 77). Right panel: dose response curve to 
Ac-RYYRIK-ol (0.01 - 1 nmol) injected i t. (AUC(0-60): saline 346 ± 23; 0.01 nmol 419 ± 13; 
0.1 nmol 556 ± 44*; 1 nmol 518 ± 46*, *p<0.05 according to ANOVA followed by the 
Dunnett's test). Points indicate the means and vertical lines the S.E.M. of 4 experiments. 
2.2. Locomotor activity assay 
In the locomotor activity assay, mice injected with saline (2 pl/mouse, i.c.v.) displayed a 
progressive reduction of spontaneous locomotor activity from 255 ± 6 to 84 ± 7 impulses/5 min 
during the 60 min time course of the experiment (Fig. 14, left panel). Ac-RYYRIK-ol 
administered in the 0.01 - 1 nmol range, caused a dose dependent reduction of locomotor 
activity compared to saline injected animals (Fig. 14 left panel). With the highest dose of 
peptide (i.e., 1 nmol) the locomotor behaviour of the animals was virtually suppressed. The 
motor inhibiting action of Ac-RYYRIK-ol was statistically significant at 0.1 and 1 nmol doses. 
(p< 0.05 vs saline, according to ANOVA followed by the Dunnett's test) (Fig. 14 right panel). 
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Fig. 14: Effects of Ac-RYYRIK-ol in the locomotor activity in mice. Left panel: dose 
response curve to Ac-RYYRIK-ol (0.01 - 1 nmol) injected i.c.v. Points indicate the means and 
vertical lines the S.E.M. of 4 separate experiments. Right panel: Data expressed as cumulative 
impulses over 60 min were used for statistical analysis. *p< 0.05 vs saline, according to 
ANOVA followed by the Dunnett's test. 
2.3. Food intake assay 
In food intake studies, the i.c.v. injection of 0.001 nmol of Ac-RYYRIK-ol did not modify 
food intake of sated mice (Fig. 15). On the contrary, when the peptide was administrated at 
0.01 and 0.1 nmol it produced a statistically significant stimulation of food intake 
(p< 0.05 vs saline, according to ANOVA followed by the Dunnett's test.) Interestingly, in this 
assay Ac-RYYRIK-ol behaved as a very potent stimulant of food intake at 0.01 nmol (Fig. 15). 
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Fig. 15: Cumulative 30 and 60 
min food intake following i.c.v. 
injection of saline or 
Ac-RYYRIK-ol (0.001, 0.01 and 
0.1 nmol). Values are means ± 
S.E.M. of 12 - 15 animals. Ordinate: 
grams / kg body weight. *p < 0.05 
vs saline according to ANOVA 
followed by the Dunnett 's test. 
2.4. Forced swimming test 
In the forced swimming test, mice treated i.c.v. with saline display an immobility time of 
190 ± 17 s (Fig. 16, left panel). Ac-RYYRIK-ol given i.c.v. in the dose range of 0.001 - 0.1 did 
not induce any significant modification of this behavioural parameter (Fig. 16 left panel). 
Conversely, as shown in Fig. 16 right panel, the well known NOP receptor antagonist peptide 
UFP-101 at 10 nmol produced a statistically significant reduction of immobility time (73 ± 19 s) 
(p< 0.05 vs saline, according to ANOVA followed by the Dunnett's test). This effect of 
UFP-101 was no longer evident when the peptide was co-administrated with 0.1 nmol of 
Ac-RYYRIK-ol. Thus indicating that Ac-RYYRIK-ol, which is inactive per se in the dose range 
tested, is able to reverse the effects of 10 nmol UFP-101. 
Saline 0.001 0.01 0.1 saline Ac-RYYRIK-ol UFP-101 Ac-RYYRIK-ol 
0.1 nmol 10 nmol + UFP-101 
Ac-RYYRIK-ol (nmol/i.c.v.) 
Fig. 16: Effects of Ac-RYYRIK-ol in the mouse forced swimming test. Left panel: dose 
response curve to Ac-RYYRIK-ol (0.001 - 0.1 nmol) injected i.c.v. Right panel: effects of 0.1 
nmol Ac-RYYRIK-ol and 10 nmol UFP-101 injected alone and co-injected on immobility time 
of Swiss mice submitted to the test. Values are means ± S.E.M. of 9 - 13 animals. *p <0.05 vs 
saline according to ANOVA followed by the Dunnett's test. 
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V. DISCUSSION 
In this thesis, biochemical and pharmacological characterization of novel NOP receptor 
ligands is described, particularly focusing on Ac-RYYRIK-ol by the use of various in vitro and 
in vivo studies. This hexapeptide alcohol was studied further for structure-activity relations by in 
vitro receptor binding, functional and pharmacological assays. 
The equilibrium dissociation constants and the maximal number of binding sites for N/OFQ 
in the literature are variable [183] which might come from the differences in the assay 
conditions and from the stability alterations of the radioligands used. In fact, the actual affinity 
of a given ligand in displacement binding experiments is highly dependent upon the radioligand 
used [146], The heptadecapeptide N/OFQ labelled with tritium (Amersham Pharmacia) on the 
leucine residue at position 14 was reported to be stable for up to 2 months [195], By using the 
Amersham product, that has the highest specific activity (160 Ci/mmol) among other 
commercially available radioisotopes [183], one binding site with similar Kj values were 
obtained in membranes from rat and CHO-NOPh both are in line with previously reported data 
[196, 197], The Bma* of the NOP receptors in rat brain membranes in this study (290.4 fmol/mg) 
is not considered significantly different than the first reported data (535 fmol/mg) [59] by 
unpaired t-test. However CHO-NOPh membranes used in this study, found to have twice as 
much NOP receptors as that of rat brain membranes. Because of different strains of animals, cell 
lines, experimental conditions, radioligand source used in various studies no clear correlation 
can be established neither of the Kd nor the Bm^ values reported. 
A series of hexapeptides of the general formula AC-RYY-R/K-W/I-R/K-NH2 were identified 
by Dr Toll's group in 1997 from a synthetic combinatorial hexapeptide library [140], Among 
these peptides Ac-RYYRJK-NH2 and Ac-RYYRWK-NH2 are the most used compounds due to 
their high affinity and selectivity for the NOP receptor [122], These hexapeptides were reported 
to behave as partial agonists at recombinant NOP receptors expressed in CHO cells ([35S]GTPyS 
binding and cAMP accumulation assays) and at the native NOP receptor expressed in the mouse 
vas deferens (mVD bioassay) [140], In this work, structure-activity studies on 
Ac-RYYRIK-NH2 principally modified on the C- and the N-terminal were summarized. The 
C-terminal modification was the replacement of the carboxyamide residue with a 
hydroxymethylen (-CH2OH) which yielded a novel hexapeptide, Ac-RYYRIK-ol with a primer 
alcohol group at C-terminal. The hexapeptide alcohol displaced [/ewcy/-3H]N/OFQ with high 
affinity, but not the opioid antagonist [3H]naloxone, indicating the selectivity of the ligand for 
NOP receptor binding sites [151]. In functional assays this peptide was first reported to be a 
competitive antagonist in the [35S]GTPyS binding performed in the rat brain membranes and 
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CHO cells expressing human NOP receptor as well as in the mouse vas deferens bioassay [151]. 
However, detailed in vitro and in vivo pharmacological characterization of the compound 
indicated that the pharmacological profile of Ac-RYYRIK-ol is more complex most likely due to its 
low efficacy agonist nature [152], The hexapeptide alcohol interacted specifically with the NOP 
receptors in rat brain membranes and recombinant cells expressing human NOP receptors 
conferring high affinity in subnanomolar range (pKj = 9.10 and 9.39 M, respectively). In rat 
brain membrane the hexapeptide alcohol was able to stimulate G-proteins with a low efficacy, 
furthermore the efficacy of the peptide was low enough to competitively antagonize (pA2 8.67) 
the N/OFQ stimulated G-protein activation. However, in membranes from CHO cells expressing 
human NOP receptor, the hexapeptide alcohol showed a clear partial agonism with a high 
potency (pEC50 8.52) and maximal stimulation of 540.9 ± 82.70 % over the basal level. Most 
likely due to the high density of the NOP receptors expressed in the cells used in the study. 
In the electrically stimulated mouse vas deferens the hexapeptide alcohol competitively 
antagonized (pA2 8.46) the inhibitory effect of N/OFQ. However, on the mouse colon tissues 
Ac-RYYRIK-ol behaved as an agonist with high potency (pEC5o 9.09). The contractile effect 
was no longer evident in colon tissues taken from mice knockout for the NOP receptor gene 
(NOP7 ) demonstrating that the effect is derived from the exclusive activation of the NOP type. 
This result also confirms the previous findings from the binding experiments [151] that the 
hexapeptide is highly selective for the NOP receptor. 
The different pharmacological activity of Ac-RYYRIK-ol at NOP receptors expressed in the 
mouse vas deferens (antagonist) and colon (agonist) is not completely surprising. In fact, very 
similar results were reported not only for the parent compound, Ac-RYYRIK-NH2, but also for 
the NOP ligand [PheV(CH2-NH)Gly2]N/OFQ(l-13)-NH2 ([F/G]N/OFQ(l-13)NH2). These 
molecules behaved as NOP antagonists in the vas deferens assay [145, 151, 198] and in the 
GTPy[35S] binding assay performed in rat brain membranes and mouse brain sections [143, 
145], while they displayed as NOP agonists in the mouse colon [144], Recently McDonald et al 
[199] reported the use of an ecdysone-inducible expression system containing CHOiNDNOPh 
(human NOP receptor expressed in Chinese hamster ovary cells) in order to examine the activity 
of a range of partial agonists. Interestingly enough, it has been demonstrated that the 
pharmacological profile of [F/G]N/OFQ(l-13)NH2 as well as that of Ac-RYYRIK-NH2 can be 
manipulated to encompass frill and partial agonism along with antagonism in the same cellular 
environment by changing, as the only variable, NOP receptor density [199]. It is worth of 
mentioning that the receptor reserve or spare receptor, which defines the ability of a given 
agonist to produce a maximal system response and also refers to the percentage of receptors not 
required for the production of a maximal response. The receptor reserve is a property of the 
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tissue (i.e., the strength of amplification of receptor stimulus inherent to the cells) and it is a 
property of the agonist (i.e., how much stimulus is imparted to the system by a given agonist 
receptor occupancy). This latter factor is quantified as the efficacy of the agonist. The actual 
value of the receptor reserve will be unique to each agonist in the given system. Different 
cellular backgrounds have different capabilities for the amplification of receptor stimuli. 
Depending on the efficiency of the stimulus-response coupling apparatus of the cell, a given 
agonist could produce no response, a proportion of the maximal response, or a maximal 
response. If the stimulus-response capability is reduced, weak partial agonists can be studied as 
antagonists to gain measurements of affinity [200], Hence, it can be suggested that 
Ac-RYYRIK-ol is, similarly to [F/G]N/OFQ(l-13)NH2 and Ac-RYYRIK-NH2, a NOP receptor 
partial agonist [152] whose estimated pharmacological activity (full, partial agonism or 
antagonism) strongly depends upon the receptor density and coupling efficiency, whereas these 
parameters are tissue/model dependent, and intrinsic activity in different tissues can vary [201], 
In summary, in vitro results demonstrated that Ac-RYYRIK-ol is a potent and selective NOP 
receptor low efficacy agonist [151,152, 202]. 
As the most interesting compound, Ac-RYYRIK-ol was characterized further in a rather 
large battery of in vivo assays in mice where it mimicked N/OFQ effects that were previously 
shown to be sensitive to NOP selective antagonists and/or no longer evident in NOP " mice. 
This applies to the effects related to: 
1. Algesia: Hyperalgesia induced by N/OFQ in mice was first demonstrated by Meunier et 
al. [3] using the hot plate test and Reinscheid et al. [2] using the tail flick test. On the contrary it 
was suggested that N/OFQ reversed the stress induced antinociception which is actually 
mediated by the endogenous opioid system, and associated with the i.c.v. injection procedure 
[90], N/OFQ was shown to reverse the morphine induced analgesia in the tail withdrawal assay 
in mouse [90] [203] and in the tail flick assay in rat [204], Dose-dependent but naloxone-
insensitive reduction of tail withdrawal latency and reversal of opioid induced analgesia was 
reported by Calo et al. [177], Correspondingly to the supraspinal pronociceptive action of 
N/OFQ, Ac-RYYRIK-ol produced a dose dependent (0.01-1 nmol) hyperalgesia with a similar 
potency and duration of effect (about 15 to 30 min) that are similar to those of N/OFQ as 
previously reported [177] [205] [134], The spinal antinociceptive effect of Ac-RYYRIK-ol was 
similar to that of N/OFQ [206, 207]. Ac-RYYRIK-ol behaves as an agonist in the in vivo 
analgesiometric tests similarly to the low efficacy agonist [F/G]N/OFQ(l-13)NH2 [177, 208], 
2. Food intake: It has been shown that intracerebroventricular administration of N/OFQ 
induces hyperphagia in sated rats [92, 209], The orexigenic effect of N/OFQ is significantly 
reduced by NOP receptor antagonist [Nphe1]N/OFQ(l-13)NH2 [210], The NOP receptor partial 
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agonist [F/G]N/OFQ(l-13)NH2 stimulated feeding alone and the co administration with N/OFQ 
did not reduce the hyperphagic effect of N/OFQ [210] [211]. Ac-RYYRIK-ol induced a dose-
dependent stimulation of food intake similarly to N/OFQ and [F/G]N/OFQ(l-13)NH2 [210], 
However, the hexapeptide alcohol was more potent, effects becoming significant at 0.01 nmol 
and having longer duration of effects when compared to N/OFQ. Thus, Ac-RYYRIK-ol 
mimicked the hyperphagic effects of N/OFQ and the partial agonist [F/G]N/OFQ(l-13)NH2 and 
behaved as an agonist in the central NOP receptors controlling the food intake [152], Recently 
the hyperphagic effects of N/OFQ was proposed to be related to inhibition of neurons that 
release alpha-melanocyte stimulating hormone (a-MSH) and oxytocin (OT) by N/OFQ [212], or 
therefore inhibition of the activity of the neuronal systems that promote termination of feeding 
are supposedly involved in the mechanism of the orexigenic effect of N/OFQ [213], 
3. Locomotor activity: N/OFQ was shown to have a biphasic effect on locomotor activity 
similar to its effects on pain mechanisms. Hypolocomotion following the i.e.v. administration of 
N/OFQ (0.1-10 nmol) was first described by Reinscheid et al [2] and pursued by other 
researchers [214] [62, 178], On the contrary, stimulation of locomotion and exploratory 
behaviour in mice has also been reported by Florin et al. However the dose range was much 
more wider than previously reported and this effect was blocked by dopamine receptor (D1 and 
D2) antagonists but not by naloxone [113], The studies on NOP receptor knockout and wild type 
mice clearly showed the involvement of NOP receptor system especially with 10 nmol N/OFQ. 
On the other hand, the relative ineffectiveness of the low dose (1 nmol) indicated that the NOP 
receptor-peptide system is not a major regulator in the control of locomotion [62, 161], 
Nevertheless, the biphasic effects were blocked by NOP receptor antagonists [215], Similarly to 
the partial agonist Ac-RYYRIK-NH2 [143] Ac-RYYRIK-ol was also shown to cause a dose 
dependent (0.01-1 nmol) inhibition of spontaneous locomotor activity in this study. Interestingly 
[F/G]N/OFQ( 1-13)NH2 behaved as a partial agonist in this assay [178], 
4. Mood disorders: Mouse forced swimming test is a model widely used for screening the 
activity of potential antidepressant drugs [216], The blockade of N/OFQ signalling obtained 
with NOP-selective antagonists promotes antidepressant-like effects in the forced swimming 
and in the tail suspension tests. This was first shown by using two NOP receptor antagonists; the 
peptide [Nphe1 ]N/OFQ( 1-13)NH2, and the non-peptide J-l 13397 [217], Later on these findings 
were confirmed and extended with the NOP receptor peptide antagonist UFP-101 [175, 218], 
Similarly to N/OFQ [175, 217, 218] Ac-RYYRIK-ol was inactive per se but able to revert the 
antidepressant-like effects of the well known NOP receptor antagonist peptide UFP-101 in the 
mouse swimming test [152], It was suggested that NOP receptor antagonists might elicit an 
antidepressant-like effect by counteracting the inhibitory effects of the endogenous N/OFQ on 
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monoaminergic systems at both pre- and postsynaptic levels, thus producing a synergistic 
potentiation of the cortical monoaminergic signal [64], 
Thus, in all the in vivo assays we performed, Ac-RYYRJK-ol behaved as a NOP agonist. 
Again, very similar results were obtained in our and other laboratories by testing the partial 
agonist [F/G]N/OFQ(l-13)NH2 and Ac-RYYRIK-NH2 in analgesiometric tests after supraspinal 
[177, 219, 220] or spinal administration [219, 220], in locomotor activity [143, 178] and food 
intake [210] studies. These data together with those obtained with Ac-RYYRlK-ol in the present 
study clearly demonstrated that low efficacy agonists behave as full agonists in these in vivo 
assays. 
NOP receptor partial agonists like Ac- R YYRIK-NH2, Ac-R YY R WK-NH2 and 
[F/G]N/OFQ( 1-13)NH2 were shown to function selectively, in particular on cardiovascular and 
renal functions. Depending on the route of administration, these compounds behave as full 
agonists (central, i.e., i.e.v.) as well as partial/antagonist (peripheral, i.e., i.v. bolus). Thus, NOP 
receptor partial agonists, especially the hexapeptides had variable pharmacological profile not 
only in the in vitro isolated tissue or cellular systems, but also in the in vivo studies related to 
cardiovascular and renal function [221], There is no simple explanation why these partial 
agonists differ functionally. Splice variants of preproOFQ/N in mouse, rat and human [23, 222-
225] were reported. Besides the presumed splice variants, and the possible formation of receptor 
oliomerization [40, 41], some of the competition and saturation binding results [31, 30, 145] 
also suggest the heterogeneity of the NOP receptor. However the functional differences of the 
partial agonists may not be due to diversity of the NOP receptor system such as central and 
peripheral since until now there is no clear evidence of the claimed NOP receptor subtypes [32], 
Therefore the alternative possibility; the different receptor density/coupling efficiencies is more 
reliable to explain these discrepacencies. It would be interesting, in future studies, to investigate 
the actions of Ac-RYYRIK-ol on cardiovascular parameters after i.c.v and i.v. administration in 
order to see if the effects change depending on the route of administration as it was seen with 
other partial agonists [221]. 
Further structure-activity studies that we performed on the hexapeptide alcohol provided 
valuable information on the structural requirements of the hexapeptide alcohol. The newly 
synthesized acetylated hexapeptide alcohol possesses two positively charged Arg (R) and two 
adjacent aromatic Tyr (Y) residues. In an attempt to understand the importance of the charged 
Arg residues, Arg / Cit replacement at first and/or fourth position was done. Consequently, in 
the binding studies intact Arg residue at the first position turned out to be essential for NOP 
receptor activation. Our finding is in line with the result observed by Ala-scanning [226], 
Interestingly enough, N/OFQ also contains two arginine side chains, at 8th and 12th position. The 
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Arg8 / Ala replacement produced a decreased functional property and receptor affinity [119]. 
Although it is feasible to assume that the hexapeptides interact in a similar manner {i.e., with the 
negatively charged side chains of EL of the NOP receptor) as N/OFQ, it has been shown by 
photo-affinity labeling that actually the hexapeptides interact with a region within the 
C-terminus of the TM-II in NOP receptor, aa. 107-113 (Gln-Gly-Thr-Asp-Ile-Leu-Leu), 
whereas N/OFQ interacts with the region of the NOP receptor: aa. 296-302 
(Thr-Ala-Val-Ile-Leu-Arg), spanning the the C-terminus of EL-ffl and the N-terminus of 
transmembrane helix VII ref. [227, 228], 
None of the citrulline-replaced hexapeptides showed better affinities than the parent peptide, 
so it can be concluded that Arg at 1st and 4lh position play an important role in the biological 
activity. Nevertheless complete affinity loss claimed the critical role of Arg at 1st position. Our 
results support the findings by Kawano et al [226] indicating the importance of Arg at 1st 
position by residual N-terminal truncation. 
The N-terminal acetyl group of the hexapeptide alcohol was further modified to determine 
its role in the binding process, and to determine to which extent its elimination or subtitution 
with other moieties is tolerated in terms of biological activity. The N-acetyl group was replaced 
by i) chloro-acetyl- or pivaloyl group that increases the steric hinderance; ii) mesyl group that 
increases steric hinderance and changes the character of the attached amide group; iii) benzoyl 
group that increases steric hinderance and confers an aromatic feature, furthermore it permits 
protonation; iv) formyl group that decreases the steric hinderance, and provides more hydrogen 
bond forming ability v) Free amino-terminal (H2N-) that eliminates steric hinderance and 
restores the basic character to the N-terminal. 
The deacetylated hexapeptide showed the lowest affinity towards the receptor however, this 
peptide had the minimum intrinsic agonist activity as well. Interestingly, substitution by the 
bulky pivaloyl (trimethylacetyl) group was less tolerated; on the other hand, the intrinsic activity 
was lowered with these replacements. Among the polar group-bearing peptides, the 
chloro-acetylated compound had the best affinity. The complete change of the N-terminal 
character with the mesyl substitution resulted in a decreased potency. As a consequence, the 
N-terminal protection with a polar group seems to be important, the N-Acetyl-Arginine group is 
essential for eliciting the molecular contact or interaction with the receptor. All the modified 
analogs of Ac-RYYRIK-ol were found to displace the opioid binding sites (by using 
[3H]naloxone) only at very high concentrations indicating their low affinities with the 
interaction with opiod receptors. 
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The novel analogues of the hexapeptide alcohol exhibited low antagonist potencies on the 
mouse vas deferens, when tested with a single concentration to antagonize the twitch response 
inhibition elicited by N/OFQ. 
NOP receptor partial agonists have recently been shown to produce functionally selective 
effects on cardiovascular and renal function in conscious rat [221], Moreover NOP partial 
agonists and antagonists were shown to have less effect than the NOP agonists on the 
internalization of hNOP receptor [229], thus it is expected for the partial agonists to induce less 
tolerance [229], 
The SAR studies confirmed the structural requirements for the hexapeptide alcohol: i) the 
positively charged Arg residues at first and fourth positions are important for the biological 
activity; in particular, the first position is crucial for ligand-receptor interaction, ii) The 
substitution of the N-terminal with various acyl groups clearly emphasized the necessity of a 
polar group to protect the N-terminal with an acetyl group. 
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v i . s u m m a r y 
Following the discovery of the nociceptin/orphanin FQ (N/OFQ) peptide receptor (NOP) 
and its endogenous ligand, an extensive search has started to find selective agonists and 
antagonists, targeting this novel receptor-ligand system, due to their therapeutic potentials. By 
the help of combinatorial chemistry a series of hexapeptides with a general formula of 
Ac-RYY-R/K-W/I-R/K-NHi were identified and found to have high NOP receptor affinity and 
selectivity [140], The present work focused on the biochemical, functional and pharmacological 
characterization of novel NOP receptor ligands, Ac-RYYRIK-oI and analogues, which appear 
from the C-terminal modification of one of the previously reported hexapeptide. This work 
consists of basic characterization of Ac-RYYRIK-ol by in vitro and in vivo experiments and the 
structure-activity relationship studies performed on the novel hexapeptide. The main findings 
are as follows: 
1. C-terminal carboxyamide modification to a hydroxymethylene yielded high affinity 
(pK; = 9.096 and 9.389 in rat brain membrane and CHO-NOPh receptors, respectively), 
selective NOP receptor ligand, Ac-RYYRIK-ol. 
2. N-terminal modifications with several acyl groups (ClAc-, pivaloyl-, formyl-, benzoyl-, 
mesyl-) decreased the affinity of the ligand towards the NOP receptor. 
3. The replacement of the positively charged arginine (Arg) residues with an uncharged 
citrulline (Cit) clearly indicated that Arg at the first posititon is essential for NOP receptor 
binding and activity. 
4. Ac-RYYRIK-ol (10 - 100 nM) competitively antagonized (pA2 = 8.67) the N/OFQ induced 
G-protein activation in rat brain membranes. However, in CHO cells expressing NOP 
receptors with binding capacities (Bmax) about two-times higher as in rat brain, the 
hexapeptide alcohol behaved as an agonist with high potency (pEC5o 8.52) and 
efficacy ( E ^ = 540.9 %). 
5. Ac-RYYRIK-ol (10 - 1000 nM) competitively antagonized (pA2 = 8.46), the inhibitory effect 
of N/OFQ in the electrically stimulated mouse vas deferens. 
6. Ac-RYYRIK-ol mimicked the contractile effects of N/OFQ in the isolated mouse colon thus 
behaving as a NOP receptor agonist (pEC5o = 9.09). This effect was no longer evident in 
colon tissues taken from transgenic mice lacking the NOP receptor gene (NOP"'") indicating 
the NOP receptor selectivity. 
7. In a series of in vivo experiments performed on Swiss mice, similarly to N/OFQ, 
Ac-RYYRIK-ol (dose range 0.001-1 nmol) was found to produce: i) pronociceptive effects 
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after intracerebroventricular (i.e.v.) administration and antinociceptive actions when given 
intrathecal^ (i.t.) in the tail withdrawal assay; ii) inhibition of locomotor activity and 
iii) stimulation of food intake after supraspinal administration. In the forced swimming test, 
Ac-RYYRIK-ol was inactive per se, but reversed the antidepressant-like effects elicited by 
the NOP receptor selective antagonist UFP-101 ([Nphe1,Arg14,Lys15]N/OFQ-NH2). Thus in 
all in vivo assays Ac-RYYRIK-ol behaved as a NOP receptor agonist. 
In conclusion, Ac-RYYRIK-ol displayed a complex pharmacological profile, which is likely 
due to the low efficacy agonist nature of this novel ligand of the NOP receptor. It is worthy of 
mentioning that NOP receptor partial agonists are drug candidates for management of 
hyponatremia and water retention (for indications such as aquaresis) in particularly because of 
their selectivity to produce renal, but not cardiovascular effects. The high potency, selectivity of 
action, and in vivo effectiveness make Ac-RYYRIK-ol a useful pharmacological tool for future 
studies in the field of N/OFQ and its NOP receptor. 
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